A Research Guide for
Colon Cancer

After a biopsy confirms colon cancer, several tests map the extent of disease:

• CT scan of the chest, abdomen, and pelvis — looks for metastatic spread, especially to the liver, lungs, and lymph nodes.
• CEA blood test (carcinoembryonic antigen) — a tumor marker. Not a diagnostic test, but a baseline value that is useful for monitoring during and after treatment.
• Complete colonoscopy — if the diagnostic colonoscopy did not examine the entire colon (sometimes an obstructing tumor prevents this), the full examination is completed later — typically around the time of surgery or soon after.
• PET scan — not routinely done for early-stage disease but may be useful in certain situations, particularly when metastatic disease is suspected.

This is also the time to order mismatch repair / MSI testing on the tumor biopsy. This single test influences nearly every downstream decision and should not wait until after surgery.

Colon cancer is staged using the TNM system, combining three measurements:

• T (Tumor depth): How deeply the tumor has grown into the bowel wall — from T1 (into the submucosa) through T4 (through the colon wall into adjacent structures).
• N (Nodes): Whether and how many nearby lymph nodes contain cancer — N0 (none), N1 (1–3 nodes), N2 (4 or more nodes).
• M (Metastasis): Whether the cancer has spread to distant organs — M0 (no) or M1 (yes, most often liver or lungs).

These combine into overall stages:

• Stage I: Tumor through the inner layers but not through the muscle wall; no lymph nodes. Usually cured by surgery alone.
• Stage II: Tumor through the muscle wall but no lymph node spread. Surgery is the primary treatment; adjuvant chemotherapy is a discussion for higher-risk cases.
• Stage III: Cancer in one or more regional lymph nodes. Surgery plus adjuvant chemotherapy is standard.
• Stage IV: Cancer has spread to distant organs. Treatment approach depends on whether metastases are removable.

After surgery, the pathology report is the definitive document. Key elements to confirm with the medical team:

• Final pathologic stage — the TNM classification based on examining the removed tissue.
• Margins — whether the edges of the removed tissue are free of cancer (negative margins are the goal).
• Lymph nodes examined — at least 12 lymph nodes should be examined for accurate staging. Fewer than 12 may under-stage the disease.
• Grade — how abnormal the cells look. High-grade (poorly differentiated) is one of the adverse features considered in treatment decisions.
• Lymphovascular invasion and perineural invasion — whether cancer cells have entered blood vessels, lymph channels, or nerves. These are adverse features that influence adjuvant treatment decisions.
• Mismatch repair / MSI status — whether the tumor is dMMR / MSI-high. This is critical for treatment planning.

• Mismatch repair / MSI testing (dMMR / MSI-high): This is the single most important molecular test in colon cancer. Roughly 15% of early-stage and 4–5% of metastatic colon cancers are dMMR / MSI-high. These tumors respond exceptionally well to immunotherapy and may signal Lynch syndrome. Testing should be done on the initial biopsy before surgery whenever possible.
• RAS mutations (KRAS and NRAS): Mutated in roughly half of colon cancers. A RAS mutation means anti-EGFR antibodies (cetuximab, panitumumab) will not work. Only “RAS wild-type” (unmutated) tumors benefit from these drugs.
• BRAF V600E mutation: Found in roughly 8–12% of cases. Associated with more aggressive biology but now treatable with a targeted combination of encorafenib plus cetuximab, which has received full FDA approval for first-line use following results from the BREAKWATER trial.
• HER2 amplification: Found in a small proportion of colon cancers. Treatable with HER2-directed therapies such as tucatinib plus trastuzumab (the MOUNTAINEER regimen).
• NTRK fusions: Rare but important. Drugs like larotrectinib or entrectinib can produce dramatic responses regardless of cancer type.
• KRAS G12C mutation: Found in a small subset. Now targetable with sotorasib plus panitumumab following the CodeBreaK 300 trial results.
• PIK3CA mutations: Found in roughly 15–20% of colon cancers. As of 2025, PIK3CA hotspot mutations identify patients who benefit from low-dose aspirin after surgery — the ALASCCA trial (NEJM 2025) showed a 51% reduction in recurrence, and this is now an NCCN guideline recommendation (v4.2025). See the “Options Building on Standard Care” section for full details.

The location of the primary tumor — right-sided versus left-sided — is itself a treatment-relevant biomarker in metastatic disease. Left-sided tumors (descending colon, sigmoid) that are RAS wild-type respond better to anti-EGFR antibodies. Right-sided tumors tend to have different mutation profiles and biology. The PARADIGM trial confirmed that in left-sided, RAS wild-type metastatic disease, panitumumab offered a survival advantage over bevacizumab as the biologic partner. This is an important part of the first-line treatment decision.

For metastatic disease, a comprehensive NGS panel that reads many cancer genes at once is the most efficient approach — it captures RAS, BRAF, HER2, NTRK, and other actionable findings in a single test. For localized disease, at minimum the mismatch repair / MSI status and, for some centers, a broader panel should be obtained. If comprehensive sequencing was not done initially and the cancer later recurs or progresses, that is the time to request it.

The detection pathway begins with the tumor’s mismatch repair / MSI testing. If the tumor is dMMR / MSI-high, the next step depends on which protein is missing:

• If MLH1 is lost, additional testing for MLH1 promoter hypermethylation (and sometimes BRAF V600E) helps distinguish between an inherited cause (Lynch syndrome) and a non-inherited, tumor-specific cause. If hypermethylation is found, the cause is usually not inherited.
• If MSH2, MSH6, or PMS2 is lost, the cause is more likely inherited, and genetic counseling with germline testing is recommended.

Germline testing (a blood or saliva test of inherited DNA) confirms whether the patient carries a Lynch syndrome mutation.

A confirmed Lynch syndrome diagnosis has direct implications for blood relatives. First-degree relatives (parents, siblings, children) each have a 50% chance of carrying the same mutation. Those who test positive face elevated lifetime risks for colon cancer, endometrial cancer, ovarian cancer, and several other cancers — but with early knowledge, they can begin intensive surveillance that catches disease at its most treatable stage.

This cascade testing — testing family members once the mutation is known — is one of the most impactful steps in all of cancer genetics. A genetic counselor coordinates this process and helps families understand results and next steps.

One of the most important findings for Lynch syndrome carriers is that aspirin may significantly reduce the risk of developing colon cancer in the first place. The CAPP2 trial (published in The New England Journal of Medicine, 2011; follow-up in The Lancet, 2020) randomly assigned 937 Lynch syndrome carriers to take aspirin 600 mg/day or placebo for 2 years. After 4 or more years of follow-up, aspirin reduced colorectal cancer incidence by approximately 55%.

• This protective effect appeared to last even after people stopped taking aspirin, suggesting a lasting change in how the bowel works.
• The CAPP3 trial (ongoing; NCT02497820) is testing whether lower aspirin doses (100 mg, 300 mg, or 600 mg) work equally well with fewer side effects — results are expected in the late 2020s.
• Aspirin for Lynch syndrome chemoprevention is a separate recommendation from the PIK3CA/aspirin recommendation for sporadic colon cancer (those are different indications for different patients).

Less common inherited conditions include familial adenomatous polyposis (FAP), which causes hundreds to thousands of polyps and typically requires surgery in early adulthood, and MUTYH-associated polyposis, which increases polyp and cancer risk through a recessive inheritance pattern. Young-onset colon cancer, a strong family history, or an unusual number of polyps should prompt genetic counseling regardless of the tumor’s MSI status.

FAP is caused by an inherited change in the APC gene (autosomal dominant; one parent passes it on). It causes hundreds to thousands of polyps to grow throughout the colon, starting in the teenage years. Without treatment, colon cancer is nearly inevitable by early adulthood.

• Detection: Genetic testing for APC variants; annual colonoscopy or sigmoidoscopy beginning at age 10–12 for at-risk family members. A finding of many adenomatous polyps (>100) in a young patient, even without a known family history, should prompt referral for genetic counseling and APC testing.
• Surgery: Prophylactic colectomy (removal of the colon) is recommended, typically in the late teens to early 20s. The two main options are a total abdominal colectomy with an ileorectal anastomosis (TAC-IRA; preserves rectal function but requires ongoing endoscopic surveillance of the remaining rectum, which still has polyp and cancer risk) or a total proctocolectomy with J-pouch (removes both colon and rectum; eliminates rectal cancer risk; requires a J-pouch reservoir with no permanent colostomy needed). The choice depends on rectal polyp burden, age, and patient preference. These discussions should take place in a specialized hereditary GI cancer program.
• Upper GI involvement: FAP also causes polyps in the stomach and small intestine, especially around the entrance to the bile duct (ampulla). Regular upper endoscopy starting in early adulthood is required. The lifetime risk of cancer at the ampullary site is about 5%.
• Desmoid tumors: Some FAP patients develop desmoid tumors — non-cancerous but locally aggressive growths, usually in the abdomen. These can be the most challenging complication of FAP to manage. Referral to a desmoid specialist is important if they develop.
• Attenuated FAP (AFAP): A milder form, also caused by APC variants but in different locations on the gene. Typically 10–100 polyps rather than hundreds. Similar cancer risk but management may be more conservative and individualized.

MAP is caused by changes in both copies of the MUTYH gene (it is recessive — both parents must each carry one copy of the changed gene for a child to develop MAP). It causes an attenuated polyposis (10–100 adenomas) with a significantly elevated colon cancer risk — but not as extreme as classical FAP.

• Lifetime colon cancer risk in MAP: approximately 43–85% without surveillance
• Management: colonoscopy every 1–2 years starting in the mid-20s; colectomy when polyp burden exceeds what can be managed endoscopically
• Carriers of only one MUTYH gene change (monoallelic): elevated risk (approximately double the general population), managed with surveillance colonoscopy starting at age 40
• MAP does not cause the upper GI or extra-intestinal features of FAP. Genetic counseling helps clarify family risk (since parents and children are typically carriers, not affected)

Serrated polyposis syndrome is defined by WHO criteria as having at least 5 serrated polyps proximal to the sigmoid colon (with 2 or more being >10 mm in size), OR at least 20 serrated polyps throughout the colon. It is underdiagnosed and not well understood — a specific genetic cause has not been identified in most patients. The colon cancer risk in SPS is approximately 7% within 5 years of diagnosis without intensive surveillance.

• Management: Annual colonoscopy with complete clearance of all polyps ≥5 mm in size. If polyp burden exceeds what can be safely managed endoscopically, colectomy is considered.
• Family risk: First-degree relatives of SPS patients have a 4-to-5-fold elevated colon cancer risk. Colonoscopy from age 40 (or 10 years younger than the proband's diagnosis) is recommended for first-degree relatives.
• SPS should be suspected in any patient found to have multiple serrated polyps at colonoscopy. Many general gastroenterologists have limited experience with this condition; referral to a hereditary colorectal program is valuable.

When evaluating any treatment claim, ask these questions:

• Where is the evidence from — a peer-reviewed journal and the NCCN guidelines, or an individual testimonial?
• Has it been tested in colon cancer specifically, in a randomized trial?
• Could it interfere with standard treatment?
• Does anyone with no financial stake in it recommend it?
• Are the doctors at major cancer centers using it?

Be especially cautious of anyone who sells the product they recommend, and of anyone who suggests standard care is harmful or unnecessary and should be replaced by a natural or alternative protocol. This advice has cost lives. The safest approach: build on standard care, never abandon it.

• Bring a second person to every appointment. One listens and asks questions; the other writes things down. Appointments routinely produce more information than one person can retain.
• Ask permission to record. Most clinics allow phone recording if asked first. A recording you can replay later is invaluable.
• Keep a single folder — paper or digital — with every report: pathology, colonoscopy, operative reports, imaging discs, molecular testing results, and lab work. You will be asked for these repeatedly, especially for second opinions and clinical trials.
• Bring marked sections of this guide to appointments and ask the doctor’s honest opinion. Cancer teams prefer engaged, prepared patients and families.

• ☐ Diagnosis confirmed on biopsy pathology report
• ☐ Staging workup ordered: CT chest/abdomen/pelvis, CEA blood test
• ☐ Mismatch repair / MSI testing ordered on the tumor (ideally on the biopsy, before surgery)
• ☐ Full molecular panel ordered if metastatic disease is present (RAS, BRAF, HER2, MSI, consider NGS)
• ☐ Complete colonoscopy confirmed (or planned for around surgery if tumor is obstructing)
• ☐ Treating center and surgeon identified — confirm colorectal cancer experience
• ☐ Records folder started: all pathology, imaging, labs in one place
• ☐ Second opinion considered, especially for complex or advanced disease
• ☐ Genetic counseling discussed if young onset, family history, or dMMR/MSI-high tumor
• ☐ Financial counselor contacted at the treating center

What is happening: The biopsy has returned. The diagnosis is confirmed. Now the critical question is whether the cancer has spread beyond the colon.

• CT scan of chest, abdomen, and pelvis: This is the primary staging test. It looks for spread to the liver (the most common site), lungs, lymph nodes, and other abdominal organs. Most centers complete this scan within the first week.
• Serum CEA (carcinoembryonic antigen): A blood tumor marker. Elevated before surgery provides a useful baseline; the number is tracked over time. Not every colon cancer makes CEA, but when it is elevated preoperatively, it becomes a useful monitoring tool.
• Colonoscopy: Confirm that the rest of the colon has been examined. If an obstructing tumor prevented full examination, a complete colonoscopy should be planned for within 3–6 months after surgery.
• Mismatch repair / MSI testing: Ideally ordered on the biopsy specimen before surgery. This test should not wait. The result affects chemotherapy selection (especially for stage II) and tells the team whether Lynch syndrome needs to be considered.

Questions to ask this week: “Are my staging CT and CEA ordered? When will results be available? Has MSI testing been requested on the biopsy already?”

Once staging is complete, the treatment path splits based on whether the cancer is localized (stages I–III) or metastatic (stage IV). Rectal cancer follows a separate path (see below).

If Stage I or II (colon only, no spread):

• Meet with colorectal surgeon to discuss operation and timing (typically within 2–4 weeks of diagnosis for non-obstructing tumors)
• If stage II and dMMR/MSI-high: confirm with medical oncologist that adjuvant chemotherapy may not be indicated (actually may be avoided)
• If stage II with high-risk features (T4, fewer than 12 lymph nodes, LVI/PNI, obstruction/perforation): discuss with medical oncologist whether adjuvant chemotherapy with FOLFOX or CAPOX is appropriate
• For patients under age 50 with any stage: ensure germline genetic testing has been discussed

If Stage III (lymph node spread but no distant metastasis):

• Surgery is the priority; plan for adjuvant chemotherapy (FOLFOX or CAPOX for 3 or 6 months) to begin within 6–8 weeks after surgery
• The adjuvant chemotherapy decision should include the MSI result, the risk category (T1–3 N1 = lower risk; T4 or N2 = higher risk), and patient preferences around neuropathy risk
• For dMMR/MSI-high stage III: consider atezolizumab + FOLFOX (ATOMIC trial protocol) if available at your center

If Stage IV (metastatic disease):

• Comprehensive molecular panel ordered immediately (RAS exons 2–4, BRAF V600E, HER2, MSI, NTRK, KRAS G12C subtype if KRAS mutant, PIK3CA)
• Metastasis surgery consultation: request evaluation by a hepatobiliary surgeon (for liver) or thoracic surgeon (for lung) to assess resectability of metastases
• If metastases are potentially resectable: systemic therapy first (conversion chemotherapy) may increase the chance of achieving curative surgery
• If clearly unresectable: begin systemic therapy matched to the molecular profile as soon as clinically feasible

If Rectal Cancer (diagnosed on biopsy from the rectum):

• MRI pelvis is mandatory (not CT pelvis) — request this immediately. High-resolution MRI measures the distance from the tumor to the surgical margin and guides whether radiation is needed before surgery
• Multidisciplinary tumor board review is especially important for rectal cancer before any treatment begins
• For most mid-to-low rectal cancers: neoadjuvant chemotherapy and/or radiation before surgery is strongly recommended

For colon cancer (non-rectal) stages I–III:

• Surgery typically occurs within 3–4 weeks of diagnosis for non-urgent cases (no obstruction, no perforation). Medically necessary delays (for pre-operative optimization, cardiac clearance, anticoagulation management) should be documented and minimized.
• Pre-operative assessment: anesthesia consultation, cardiopulmonary evaluation if indicated, nutritional status assessment (a dietitian consultation before surgery reduces complications)
• For patients with temporary or permanent ostomy planned: WOC (wound, ostomy, continence) nurse consultation before surgery to mark the stoma site correctly
• Blood thinners: most should be stopped 5–7 days before surgery; specific anticoagulants may require bridging; discuss with surgeon and prescribing physician early

For rectal cancer (locally advanced with neoadjuvant planned):

• Radiation planning and simulation appointment (usually within 2 weeks of multidisciplinary tumor board review)
• Chemotherapy administration (concurrent with radiation, or induction before radiation in a TNT approach) begins in this window
• Total neoadjuvant therapy (TNT): delivers all systemic chemotherapy before surgery (instead of after). The main advantages are higher rates of tumor shrinkage before surgery and, for some patients, the possibility of avoiding surgery altogether if the tumor disappears completely

• Final pathology report: Review with your surgeon. Confirm: final T and N stage, number of lymph nodes examined (should be ≥12), margin status, LVI (lymphovascular invasion), PNI (perineural invasion), MSI/MMR result if not done pre-operatively
• Medical oncology appointment: Should occur within 4–5 weeks of surgery to discuss adjuvant chemotherapy decision (or confirm observation for stage I/dMMR stage II)
• ctDNA testing: At 4–8 weeks post-surgery, circulating tumor DNA testing (a blood test) may identify microscopic disease not visible on scans. This is not yet standard of care but is increasingly offered and helps guide adjuvant decisions in some centers
• Starting adjuvant chemotherapy: Goal is to begin within 6–8 weeks of surgery (ideally 4–6 weeks). Delays beyond 8–12 weeks reduce the benefit. Port placement (if using FOLFOX infusion) should be coordinated ahead of the first treatment cycle
• For rectal cancer post-neoadjuvant: Response assessment at 8–12 weeks after completing radiation (MRI pelvis + endoscopy + physical exam). Surgery timing depends on response. If a complete clinical response is documented, watch-and-wait (organ preservation) may be offered at specialized centers

• A dedicated colorectal or gastrointestinal cancer program with a multidisciplinary tumor board
• Surgeons who perform a high volume of colon cancer operations
• Routine molecular testing and genetic counseling services
• An active clinical trials program
• Supportive care services: oncology dietitians, social workers, palliative care

For patients in Utah and the Mountain West, Huntsman Cancer Institute is the NCI-designated comprehensive cancer center for the region, with a multidisciplinary GI cancers program, an integrated early-onset colorectal cancer program, a hereditary GI cancer genetics program, and the largest early-phase trials portfolio in the region. Main line: 801-587-7000.

A well-chosen second opinion is valuable for stage IV or recurrent disease, uncommon molecular features, complex surgical questions, or simply to build confidence in the plan. Most of this can be done remotely without delaying treatment. Several major centers — MD Anderson, Memorial Sloan Kettering, Mayo Clinic, and Dana-Farber — offer structured remote second-opinion programs.

A second opinion is not a sign of distrust. Experienced oncologists expect it and support it.

The type of operation depends on the tumor’s location:

• Right hemicolectomy: For tumors in the cecum, ascending colon, or hepatic flexure. Removes the right colon and reconnects the small intestine to the remaining colon.
• Extended right hemicolectomy: For tumors in the transverse colon, extends the removal to include more of the colon.
• Left hemicolectomy: For tumors in the descending colon. Removes the left colon.
• Sigmoid colectomy: For tumors in the sigmoid colon. Removes the sigmoid and reconnects the remaining colon to the rectum.

In each case, the reconnection of the bowel ends (the anastomosis) is made during the same operation. Most patients do not need a permanent ostomy for colon cancer, though some may have a temporary one.

• Complete mesocolic excision: A technique that removes the tumor along with the intact sheet of tissue (mesentery) containing the lymph nodes and blood vessels. This is the technical standard for a high-quality operation.
• Lymph node harvest of at least 12: The pathologist should examine at least 12 lymph nodes for accurate staging. Fewer than 12 may under-stage the disease and lead to under-treatment. This is both a surgical quality measure and a pathology quality measure.
• Negative margins: The edges of the removed tissue should be free of cancer.

After reviewing the pathology report, patients should confirm the margin status and lymph node count with their surgical team.

Colon cancer surgery can be performed through small incisions using a camera (laparoscopic or robotic) or through a larger traditional incision (open surgery). Multiple trials have shown equivalent cancer outcomes with minimally invasive approaches, with the additional benefits of less pain, faster recovery, shorter hospital stays, and fewer wound complications. Most colon cancer operations at experienced centers are now performed minimally invasively.

Most colon cancer patients do not need a permanent ostomy. In some situations a temporary ostomy is created to protect a healing bowel connection, and this is later reversed in a smaller second operation. When a permanent ostomy is necessary, it is very livable — patients work, travel, exercise, and lead full lives. A certified ostomy nurse (WOC nurse) is the most valuable resource and should be consulted before surgery whenever an ostomy is planned.

Many centers use enhanced recovery after surgery (ERAS) protocols: early mobilization, early eating, minimizing opioids, and goal-directed fluid management. These are associated with faster recovery and shorter hospital stays. The window for starting adjuvant chemotherapy (when indicated) is typically six to eight weeks after surgery, and recovery should be planned with this timeline in view.

The goal is always to remove all cancer with a clear margin while preserving as much bowel and sphincter function as safely possible. For some tumors, that goal can be fully achieved while keeping the sphincter. For others, removing the sphincter along with the tumor is the only way to ensure an adequate margin.

• Low anterior resection (LAR): The most common sphincter-saving operation for rectal cancer. The rectum is removed and the colon is reconnected to the remaining rectal stump. Almost always done with a protective temporary ostomy (usually an ileostomy), which protects the healing connection below. The temporary ostomy is reversed in a smaller second operation 3–6 months later, after a leak test confirms healing. LAR is typically offered for tumors 5 cm or more from the anal opening.
• Abdominoperineal resection (APR): Used for tumors that involve the sphincter muscle itself, or that are so close that an adequate cancer-free margin cannot be achieved without removing the sphincter. The entire rectum and anus are removed through two incisions (one in the abdomen, one in the perineum around the anus). The result is a permanent colostomy. APR is not a surgical failure — it is the right operation when the tumor requires it, and it provides the same cancer control as sphincter-saving operations in this setting.
• Intersphincteric resection (ISR): For ultra-low tumors involving the internal but not external sphincter muscle. A specialized technique that allows sphincter preservation in carefully selected patients, performed by surgeons with specific expertise. Requires pre-operative anorectal function testing to ensure the external sphincter is strong enough to compensate.
• Transanal minimally invasive surgery (TEM/TAMIS): For small, early-stage rectal tumors (T1, well-differentiated, no lymph node spread) that can be removed through the anus without abdominal incisions. Only appropriate when cancer is truly early-stage; requires dedicated pre-operative MRI and experienced surgeon.

Low anterior resection syndrome (LARS) is one of the most under-discussed consequences of rectal cancer surgery. It affects 60–80% of patients who have a low anterior resection, and many patients are surprised by its severity because surgeons often focus the pre-operative conversation on cancer control.

LARS is a collection of bowel symptoms that develop when the rectum is removed and replaced by a colon-to-rectum or colon-to-anus anastomosis. The rectum is not just a tube — it is a reservoir that holds stool and coordinates when bowel movements happen. When it is removed, the colon substitutes but never perfectly replicates this function.

LARS symptoms:

• Increased stool frequency: 5–10 or more bowel movements per day is common in the first year
• Urgency: Inability to delay a bowel movement more than a minute or two; urgency incontinence
• Clustering: Multiple closely spaced bowel movements within a short period, followed by long gaps
• Soiling and leakage: Incomplete emptying leads to soiling; gas control may be impaired
• Constipation alternating with loose stools: Some patients develop a paradoxical pattern

What helps:

• Pelvic floor physiotherapy: The most evidence-supported intervention. Biofeedback and pelvic floor training improve urgency, clustering, and soiling. Ask for a referral before or immediately after surgery
• Dietary modifications: Fibre supplementation (psyllium) can improve stool consistency. Identifying trigger foods (coffee, alcohol, spicy foods) helps reduce clustering episodes
• Transanal irrigation (TAI): A washout technique using a pump to irrigate the bowel; reduces LARS severity in multiple clinical studies. Involves a learning curve but significant improvement for many patients
• Medications: Loperamide before meals reduces urgency. Low-dose amitriptyline or colestyramine may help clustering patterns
• Time: LARS usually improves over the first 12–24 months as the bowel adapts. Most patients find a workable routine. Expect active adjustment during this period

LARS can significantly affect quality of life, work, social activities, and travel. It deserves direct conversation with the surgical team before the operation, a written survivorship plan after, and a referral to a specialist in pelvic floor disorders if symptoms are severe.

For patients with rectal cancer whose tumor completely disappears after chemotherapy and radiation — confirmed on MRI and colonoscopy — a growing number of specialized centers now offer an alternative to surgery called watch-and-wait (also called organ preservation or non-operative management).

How it works: After completing neoadjuvant therapy, patients undergo careful assessment (MRI with diffusion-weighted imaging, colonoscopy/endoscopy, and blood CEA measurement). If all tests show a complete disappearance of the tumor, the patient enters a structured surveillance program rather than proceeding to surgery. Surveillance involves endoscopy and MRI every 3–4 months for the first 2 years, then less frequently.

The data: From the International Watch & Wait Database (a multicenter registry of over 900 patients): approximately 25–30% of patients will develop a tumor regrowth, most within the first 12–18 months. When regrowth occurs, about 80–90% of patients can be successfully salvaged with surgery at that point. The approximately 70–75% who do not develop regrowth avoid surgery entirely, preserving the rectum and avoiding the functional consequences of a permanent or temporary colostomy.

Who is the ideal candidate: Patients with a documented complete clinical response confirmed by MRI and endoscopy; particularly valuable for ultra-low rectal tumors where the surgical alternative is APR with permanent colostomy. Watch-and-wait should only be offered at centers with structured protocols, dedicated MRI reading expertise, and rigorous follow-up capabilities.

Colon cancer most commonly spreads to the liver and lungs. For a carefully selected group of patients, removing these metastases through surgery or a local treatment (ablation) can lead to long-term remission and cure — not just disease control. This is one of the most important and often under-recognized facts about stage IV colon cancer.

Liver metastases:

• Who can have surgery: Patients whose liver metastases can be completely removed with adequate liver tissue remaining (generally ≥20–30% of the liver must remain after resection). The number of metastases and their location matter less than whether complete removal is technically achievable. There is no absolute limit on the number that can be removed if the liver remnant is adequate.
• 5-year survival after liver resection: Approximately 30–50% for well-selected patients. This is dramatically better than systemic therapy alone.
• Converting unresectable to resectable (conversion therapy): Patients whose liver metastases are initially too large or too numerous for surgery may become eligible after a period of systemic chemotherapy that shrinks the tumors. This is specifically called conversion therapy and is distinct from palliative treatment. FOLFOXIRI + bevacizumab, or targeted therapy in BRAF V600E or RAS WT tumors, can achieve high response rates (50–65%). Reassessment with a hepatobiliary surgeon every 2–3 cycles is important.
• Ablation: For small liver metastases (≤3 cm), radiofrequency ablation (RFA) or microwave ablation (MWA) can destroy tumors using heat through a needle inserted into the liver under imaging guidance. Ablation can be combined with surgical resection, or used for patients not suitable for surgery.
• SIRT (selective internal radiation therapy / Y-90): Tiny radioactive microspheres injected directly into the hepatic artery to treat liver-confined disease. Used as a bridge to resection or for liver-dominant disease not amenable to surgery or ablation.

Lung metastases:

• Pulmonary metastasectomy (surgical removal of lung metastases) is also associated with long-term survival in carefully selected patients — typically those with limited lung-only disease, good pulmonary reserve, and controlled primary tumor.
• Stereotactic body radiation therapy (SBRT) offers a non-surgical alternative for small lung metastases in patients who are not surgical candidates or prefer non-operative management.

• Diagnosis confirmed; staging workup completed
• Molecular testing ordered (at minimum, mismatch repair / MSI)
• Surgeon and treating center selected
• Records folder assembled: pathology, imaging, labs, medication list, insurance information
• Second opinion considered; genetic counseling discussed
• Financial counselor engaged

• Operation performed; enhanced recovery protocol followed
• Final pathology report reviewed: stage, margins, lymph node count (≥12), molecular results
• Adjuvant chemotherapy timeline discussed (if indicated, aim to begin within 6–8 weeks)
• Ostomy nurse engaged if applicable

• Adjuvant chemotherapy decision made using stage, adverse features, MSI status, and patient factors
• Port placed if indicated; treatment begins
• Side effects — especially neuropathy — reported at every visit
• Supportive care and exercise habits established

• Structured surveillance schedule: periodic CEA, CT scans, colonoscopy
• Written survivorship care plan obtained
• Long-term effects of treatment addressed: neuropathy, bowel function, emotional health
• Structured exercise maintained

• Recurrence confirmed and fully restaged
• Molecular profile re-checked (tumor can evolve under treatment pressure)
• Resectability assessed by a multidisciplinary team including a metastasis surgeon
• Treatment matched to molecular profile; clinical trials considered
• Second opinion obtained at a major center

Stage I colon cancer has an excellent prognosis with surgery alone. Adjuvant chemotherapy is not recommended.

Most stage II patients do well with surgery alone. However, certain “high-risk” features make recurrence more likely and tilt the conversation toward adjuvant chemotherapy:

• T4 tumor (cancer has grown through the colon wall into adjacent structures)
• Poorly differentiated (high-grade) histology
• Lymphovascular invasion or perineural invasion
• Bowel obstruction or perforation at presentation
• Fewer than 12 lymph nodes examined (inadequate staging)
• Positive or close margins

An important exception: stage II tumors that are dMMR / MSI-high actually have a better prognosis and appear not to benefit from fluoropyrimidine-only chemotherapy. For these patients, observation after surgery is often appropriate.

This is genuinely a gray area in oncology, and the decision should be made through a detailed conversation weighing the tumor’s specific features against the patient’s age, health, and preferences.

For stage III colon cancer (lymph node involvement), adjuvant chemotherapy meaningfully reduces the risk of recurrence and improves survival. The standard regimens are:

• FOLFOX: Infusional 5-fluorouracil, leucovorin, and oxaliplatin — given intravenously every two weeks.
• CAPOX (also called CAPEOX or XELOX): Capecitabine pills plus intravenous oxaliplatin — given in three-week cycles.
• Single-agent fluoropyrimidine (5-FU/leucovorin or capecitabine alone) — for patients who cannot tolerate oxaliplatin due to age, frailty, or other health conditions.

The goal is to begin within six to eight weeks of surgery. Delays beyond this window reduce the benefit.

The DPYD gene controls how the body processes fluoropyrimidine chemotherapy (5-FU and capecitabine). Certain inherited DPYD variants dramatically increase the risk of life-threatening toxicity. The FDA has added a boxed warning recommending DPYD testing before starting these drugs. If a variant is found, the dose is adjusted or an alternative approach is used. This test should be requested before the first dose of chemotherapy.

The IDEA findings allow oncologists to tailor duration based on risk:

• Lower-risk stage III (T1–3, N1): Three months of CAPOX achieved nearly the same recurrence reduction as six months, with substantially less neuropathy. Three months is a reasonable choice for many of these patients.
• Higher-risk stage III (T4 or N2): The full six months showed a more meaningful advantage. Six months is generally recommended for higher-risk disease.

This framework means the duration conversation is individualized — not a one-size-fits-all answer. The key trade-off is between a small potential gain in recurrence reduction with longer treatment versus the cumulative nerve damage (neuropathy) from additional oxaliplatin cycles.

Oxaliplatin causes peripheral neuropathy — numbness and tingling in the fingers and toes — that accumulates with each dose and can become permanent if treatment continues past the point of significant damage. Managing it well requires proactive communication:

• Report neuropathy specifically and early at every visit. Do not minimize symptoms.
• The oncologist can reduce the oxaliplatin dose, lengthen the interval between cycles, or stop oxaliplatin while continuing the fluoropyrimidine backbone — decisions that protect long-term hand and foot function.
• During infusions, the acute cold-triggered form can be eased by avoiding cold drinks, cold air, and cold objects for a few days after each dose.
• For established neuropathy, duloxetine has the best evidence for symptom relief. Physical and occupational therapy help with function and safety.

The ATOMIC trial showed that adding atezolizumab (an immunotherapy drug) to standard FOLFOX adjuvant chemotherapy for stage III dMMR colon cancer improved disease-free survival. This is now part of the NCCN guidelines for stage III dMMR disease. Patients with stage III dMMR colon cancer should specifically ask their oncologist whether the ATOMIC regimen (FOLFOX plus atezolizumab) is appropriate for them.

For patients with localized dMMR colon cancer, early data from the NICHE-2 study and similar trials have shown remarkable results with immunotherapy given before surgery — including some patients achieving a pathologic complete response. This raises the possibility that some dMMR patients might safely reduce or even avoid surgery, though this remains an active area of research rather than a settled standard.

For now, surgery remains the standard approach for localized colon cancer. However, establishing dMMR status as early as possible — ideally on the biopsy, before surgery — is important so that a neoadjuvant immunotherapy trial can be discussed while the standard surgical option is still fully available.

For metastatic colon cancer that is dMMR / MSI-high, immunotherapy has become the preferred first-line treatment. Two landmark trials established this:

• KEYNOTE-177: Showed pembrolizumab alone as superior to standard chemotherapy as first-line treatment for dMMR metastatic colorectal cancer, with better progression-free survival and fewer side effects.
• CheckMate 8HW: Showed the combination of nivolumab plus ipilimumab was superior to both chemotherapy and nivolumab alone, with more than two-thirds of patients still responding at two years.

For patients with metastatic dMMR disease, confirming MSI status before starting any systemic treatment is critical — it can mean immunotherapy instead of chemotherapy as the first-line approach.

Studies including the DYNAMIC trial and the GALAXY / CIRCULATE-Japan program have explored using post-surgical ctDNA status to identify which patients have residual microscopic disease (ctDNA-positive) and might benefit most from adjuvant chemotherapy, and which patients are likely cured by surgery alone (ctDNA-negative) and could potentially be spared chemotherapy.

This is a fast-moving area. ctDNA-guided adjuvant decisions are increasingly available in clinical practice, though many oncologists still consider the evidence evolving. It is a reasonable topic to discuss with the oncology team, especially for patients in the gray zone — such as stage II with high-risk features — where the adjuvant decision is genuinely uncertain.

Practical access: Several commercially available ctDNA tests are tumor-informed (they sequence the patient’s own tumor first, then look for those specific mutations in blood), including Signatera (Natera) and others. The oncology team orders the test and sends a blood sample to the laboratory. Turnaround is typically 1–2 weeks. Insurance coverage varies: many commercial plans and Medicare cover ctDNA testing for colorectal cancer when ordered for specific clinical indications (e.g., post-surgical MRD assessment), but pre-authorization may be required. If coverage is denied, the testing companies often have financial-assistance or patient-access programs that reduce or eliminate the out-of-pocket cost. Ask the oncology team or the lab’s patient-services line about current coverage policies.

Beyond adjuvant decisions, ctDNA testing is increasingly used during surveillance to detect recurrence before it appears on imaging. A rising ctDNA level can signal returning cancer earlier than standard CEA and CT monitoring. Several tumor-informed tests are commercially available. However, ctDNA monitoring should be understood as an emerging tool used alongside standard surveillance, not yet a replacement for it. A positive or rising result should prompt careful conversation with the oncology team, not panic.

The phase 3 CHALLENGE trial (CCTG CO.21, published in the New England Journal of Medicine in 2025, 889 patients) randomly assigned patients who had completed adjuvant chemotherapy for stage III or high-risk stage II colon cancer to either a structured exercise program or general health education. The exercise group had a significantly lower risk of recurrence or death (hazard ratio 0.72), translating into a five-year disease-free survival of 80% vs. 74%. Overall survival was also significantly improved (hazard ratio 0.63). This is an effect size comparable to what some drugs achieve.

The practical message: structured, regular physical activity after treatment is now an evidence-based part of survivorship care, not merely good general advice. The program centered on roughly the equivalent of brisk walking for 45 to 60 minutes several times a week, built gradually with support. Patients should ask their oncology team about exercise referrals or rehabilitation services.

• Diet: A generally healthy diet is sensible — rich in vegetables, fruit, whole grains, and fiber, and limited in red and processed meat and alcohol. This is associated with better outcomes in observational studies. No specific diet has been proven to treat colon cancer, and restrictive diets that cause weight loss during treatment can do harm. An oncology dietitian is the right resource.
• Supplements: Most are unproven, and some interfere with chemotherapy or liver enzymes. Every supplement should be reviewed with the oncology team before use.
• Aspirin: See the dedicated aspirin section below — the ALASCCA trial published in September 2025 has made this a guideline-endorsed recommendation for specific patients.

For patients of reproductive age, chemotherapy can affect fertility. Both men and women should discuss fertility preservation options — sperm banking, egg or embryo freezing — before chemotherapy begins. Once treatment starts, the window for some of these options closes. The oncology team can provide referrals to reproductive specialists, and this conversation should happen early in the treatment planning process.

Two major randomized trials have now established aspirin’s benefit specifically in PIK3CA-mutated colorectal cancer:

• ALASCCA trial (NCT02647099; NEJM, September 2025, 3,500+ patients): Patients with resected colon cancer carrying PIK3CA hotspot mutations who took aspirin (160 mg daily) for 3 years had a 3-year recurrence rate of 7.7% compared to 14.1% with placebo — a 51% reduction in risk of recurrence.

STANDARD — for PIK3CA-mutated tumors specifically.

What this means for patients:

• PIK3CA mutation testing should be requested as part of the molecular workup. If testing was not done initially, ask the oncologist whether archived tumor tissue can still be tested.
• Roughly 15–20% of colon cancers carry PIK3CA hotspot mutations.
• The benefit is specific to PIK3CA-mutated tumors. There is no strong evidence that aspirin helps patients whose tumors do not carry this mutation.
• Aspirin carries a real risk of gastrointestinal bleeding. The decision to start aspirin must weigh the recurrence reduction against the individual patient’s bleeding risk, and it should be made with the oncology team.
• This is a low-cost, well-tolerated oral medication — if the molecular profile fits and bleeding risk is acceptable, it represents a meaningful addition to standard care.

Source: NEJM 2025 (ALASCCA trial).

PSK (Polysaccharide K, brand name Krestin) is a protein-bound polysaccharide derived from Trametes versicolor (Turkey Tail mushroom). It has been a licensed pharmaceutical drug in Japan since the 1980s, given orally alongside adjuvant chemotherapy for colorectal and other cancers.

• A 2024 meta-analysis of 3 centrally randomized Japanese trials (1,094 colorectal cancer patients) showed: overall survival risk ratio 0.71 (p=0.006) and disease-free survival risk ratio 0.72 (p=0.003), favoring PSK.
• In Stage III patients specifically: 5-year disease-free survival was 60% with PSK versus 32.1% without; 5-year overall survival was 74.6% versus 46.4%.
• PSK is an oral immune modulator with a favorable side-effect profile. It was used alongside older Japanese chemotherapy regimens (tegafur-uracil, mitomycin C), which differ from the oxaliplatin-based regimens that are the current international standard.
• Source: PMC 2024 meta-analysis.

EMERGING — Supported in the Japanese oncology context, where it has decades of clinical use.

Vitamin D status has been studied as a potential modifier of colon cancer outcomes. Two notable trials have examined high-dose vitamin D3 supplementation:

• SUNSHINE trial (139 patients, Dana-Farber Cancer Institute): Patients with metastatic colorectal cancer receiving standard chemotherapy were randomized to high-dose vitamin D3 (8,000 IU loading dose then 4,000 IU daily) versus standard-dose (400 IU daily). Median progression-free survival was 13 months with high dose versus 11 months with standard dose, favoring the high-dose arm.
• AMATERASU trial (417 patients, Japan): In the overall population, the benefit did not reach traditional statistical significance. However, a subgroup analysis of patients with poorly differentiated tumors showed a striking difference: 5-year relapse-free survival of 91% versus 63%.
• Source: JAMA 2019.

EMERGING — The signal is real but neither trial met its primary endpoint in the overall population. This is suggestive, not definitive.

Vitamin D sufficiency is independently important for bone health and general well-being. Having vitamin D levels checked and correcting deficiency is reasonable for all cancer patients. Whether high-dose supplementation provides additional anti-cancer benefit remains an open question — discuss with your oncology team.

Hangeshashinto (TJ-14) is a traditional Japanese Kampo medicine that has been studied as a mouthwash to reduce oral mucositis during fluoropyrimidine-based chemotherapy — a common and painful side effect.

• The HANGESHA-C trial (double-blind, placebo-controlled Phase II, 93 colorectal cancer patients receiving fluoropyrimidine-based chemotherapy): Duration of grade 2 or higher oral mucositis was 5.5 days with TJ-14 mouthwash versus 10.5 days with placebo (p=0.018) — roughly halving the duration of significant mouth sores.
• Source: PMC.

EMERGING — A single well-designed trial with a meaningful reduction in a common side effect. Discuss with your oncology team if oral mucositis is a problem during chemotherapy.

NEGATIVE — Harmful. Do not use.

The single most important question in stage IV colon cancer: can the metastases be completely removed by surgery? A patient with a limited number of liver or lung metastases that a skilled surgeon can resect has a genuinely different outlook — with real cure rates — from a patient with widespread disease. This question requires a multidisciplinary review that includes a surgeon experienced in metastasis surgery (hepatobiliary or thoracic surgeon).

Even if metastases are not initially resectable, chemotherapy may shrink them enough to make surgery possible (a “conversion” strategy). So the question is not just “is it removable now?” but “could it become removable after treatment?”

First-line treatment for metastatic colon cancer combines a chemotherapy backbone with a biologic drug:

• Chemotherapy backbones: FOLFOX, FOLFIRI, or FOLFOXIRI (for fitter patients when a strong, rapid response is needed). These are the combinations that form the foundation of treatment.
• Biologic partners:
  • Bevacizumab (anti-VEGF) — works across tumor subtypes and is a common partner for right-sided tumors.
  • Cetuximab or panitumumab (anti-EGFR) — effective only in RAS wild-type tumors and most effective in left-sided tumors. The PARADIGM trial confirmed a survival advantage for panitumumab in this setting.

The choice of biologic partner depends on the tumor’s molecular profile (especially RAS status) and sidedness.

For liver-dominant metastatic disease, additional local treatments may complement systemic therapy:

• Hepatic artery infusion (HAI): Direct delivery of chemotherapy to the liver through its blood supply. Available at specialized centers (notably Memorial Sloan Kettering) for selected patients.
• Ablation and stereotactic body radiation (SBRT): Used for small metastases that are not easily accessible by surgery or as a complement to resection.

For peritoneal disease (cancer on the abdominal lining), cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) may be considered at experienced centers for selected patients. The PRODIGE 7 trial showed that HIPEC may not add substantial benefit beyond thorough cytoreductive surgery alone in some settings, so patient selection and center expertise are critical.

After an initial course of intensive treatment, maintenance therapy — a less intensive regimen to sustain disease control while reducing side effects — is often used. Common maintenance approaches include a fluoropyrimidine with or without bevacizumab, while holding oxaliplatin to limit neuropathy. The treatment is paused or re-intensified based on scan results.

BRAF V600E-mutant colon cancer was historically one of the most challenging subtypes. The BEACON trial established encorafenib plus cetuximab as effective in previously treated patients. More recently, the BREAKWATER trial (NCT04607421) demonstrated the benefit of encorafenib plus cetuximab plus mFOLFOX6 in the first-line setting, earning FDA accelerated approval in December 2024 and full traditional approval on February 24, 2026 for first-line use. Patients with BRAF V600E-mutant disease should ensure this is identified through molecular testing and discuss targeted treatment with their oncologist.

A small percentage of colon cancers have HER2 amplification. The MOUNTAINEER trial showed that the combination of tucatinib plus trastuzumab produced meaningful responses in HER2-amplified, RAS wild-type metastatic colorectal cancer. Trastuzumab deruxtecan (an antibody-drug conjugate) has also shown activity in this setting in the DESTINY-CRC trial. HER2 testing should be part of the molecular panel for metastatic disease.

The KRAS G12C mutation, found in a small subset of colon cancers (˜3–4% of mCRC), is now targetable with two FDA-approved combinations:

• Sotorasib plus panitumumab (CodeBreaK 300, NCT05198934) — FDA approved January 16, 2025. Showed improved response rates and progression-free survival compared with standard treatment in KRAS G12C-mutant mCRC.
• Adagrasib plus cetuximab (KRYSTAL-10, NCT04793958) — FDA accelerated approval June 2024. Response rates approximately double those of adagrasib monotherapy. This is now an NCCN-recommended option for second-line or later KRAS G12C-mutant mCRC.

KRAS G12C testing should be part of the molecular panel for all patients with metastatic colon cancer, as these approvals represent the first time KRAS — once considered undruggable — can be directly targeted.

NTRK gene fusions are rare but produce dramatic responses to drugs like larotrectinib and entrectinib, regardless of cancer type. These are identified through comprehensive NGS panels. Other rare but actionable findings continue to emerge, reinforcing the value of broad molecular testing in metastatic disease.

When first-line treatment stops working, several later-line options are available:

• Regorafenib: An oral multikinase inhibitor for patients who have progressed through standard treatments.
• Trifluridine/tipiracil plus bevacizumab: The SUNLIGHT trial showed that adding bevacizumab to trifluridine/tipiracil improved overall survival in refractory metastatic colorectal cancer.
• Fruquintinib: An oral VEGFR inhibitor shown to improve survival in the FRESCO-2 trial for heavily pretreated patients.

At every step in the treatment sequence, clinical trials should be considered — the options through trials are often the most promising, and eligibility broadens as standard options are exhausted.

After curative treatment, recurrence is monitored through structured surveillance: periodic CEA blood tests, CT imaging, and colonoscopy. A rising CEA, a new finding on a scan, or a new lesion on colonoscopy can signal recurrence. Increasingly, ctDNA testing may detect recurrence earlier than standard monitoring.

A suspected recurrence should prompt a thorough re-evaluation, not panic or rushed decisions. Two things are established first: confirm that it is truly recurrence (some scan findings turn out to be benign), and map the full extent with complete restaging.

This is the most important fact about recurrence: a colon cancer recurrence that is limited — a small number of metastases in the liver or lungs — can often be treated with curative intent. Surgery to remove the recurrent disease, sometimes combined with chemotherapy and local treatments, offers a real chance of long-term survival and cure. The same critical question applies: is the recurrence resectable, or could it become resectable? This requires a multidisciplinary review with a surgeon experienced in metastasis surgery.

When cancer recurs, it should be molecularly re-tested. Tumors can evolve under the pressure of prior treatment, and a blood-based ctDNA panel or biopsy of the recurrent disease may reveal new actionable findings or confirm existing ones. If comprehensive sequencing was never done initially, recurrence is the time to request it.

• Localized dMMR disease: Trials of neoadjuvant (pre-surgery) immunotherapy and organ-preservation strategies.
• Stage II–III disease: Trials using ctDNA to guide adjuvant therapy decisions.
• Metastatic disease: Trials of new targeted drugs, immunotherapy combinations (including efforts for mismatch-repair-proficient tumors), and novel agents.
• Recurrent or heavily pretreated disease: Trials are often the source of the most promising options once standard treatments have been used.

• Start with the treating center’s clinical trials office. The oncology team knows which trials are open and which the patient may qualify for.
• Search ClinicalTrials.gov — the official U.S. database. Filter by condition, recruiting status, and location.
• Use a patient navigation service. The Colorectal Cancer Alliance (877-422-2030, ccalliance.org), Fight Colorectal Cancer (fightcrc.org), and the National Cancer Institute (1-800-4-CANCER, cancer.gov) all help match patients to trials.
• Ask at a second-opinion visit. A major center may have trials the local team does not.

Trial enrollment moves faster when paperwork is assembled in advance. Keep ready: all pathology reports, molecular testing results, operative reports, imaging reports and images, complete medication list, full medical history, recent lab results, and insurance information. By federal law, most insurance plans must cover the routine care costs of clinical trial participation, and the experimental drug is generally provided at no cost by the trial sponsor.

When a patient does not qualify for a trial but the family wants access to an experimental drug, the FDA’s expanded access (compassionate use) program may provide a path. This requires the drug company’s agreement, FDA authorization, and the local hospital’s participation. The oncology team can initiate the process where appropriate.

• Aerobic activity: 150 minutes per week of moderate-intensity exercise (brisk walking, cycling, swimming) is a reasonable target. Many patients can achieve this even during chemotherapy, adjusted for fatigue and neutropenia.
• Resistance training: 2–3 sessions per week of light-to-moderate resistance exercise helps prevent muscle loss (sarcopenia), which is associated with worse outcomes and poorer tolerance of chemotherapy. Simple bodyweight exercises or resistance bands at home are adequate.
• Timing around infusions: On infusion days and the following 1–2 days, rest as needed. Resume activity as energy allows. Avoiding exercise with a very low white cell count (especially <500/µL ANC) is standard safety advice.
• Oxaliplatin and cold: Cold-induced neuropathy from oxaliplatin can be triggered by cold weather or cold objects. Exercise outdoors in cold temperatures may worsen symptoms. Indoor exercise or appropriate layering is advisable in cold months.
• Ostomy considerations: Patients with a stoma can exercise, including swimming and resistance training. High-impact or high-intra-abdominal pressure activities should be introduced gradually with the team's guidance. A certified wound/ostomy nurse can advise on pouch security.

• 150–300 min/week moderate aerobic activity is the ACSM and NCCN recommendation for cancer survivors. Higher volumes are associated with greater reductions in recurrence risk.
• Resistance training 2×/week to rebuild muscle mass, improve insulin sensitivity, and reduce fatigue. Especially important after pelvic or abdominal surgery.
• Avoid prolonged sitting: Sedentary time independent of exercise appears to increase cancer risk. Breaking up sitting every 30–60 minutes helps.
• Cancer exercise programs: Many NCI-designated centers (including Huntsman Cancer Institute) offer oncology-specific exercise programs staffed by certified exercise oncologists. Ask your team for a referral to the cancer rehabilitation or exercise oncology program.
• LIVESTRONG at the YMCA: A free or low-cost exercise program designed for cancer survivors available at many YMCA locations nationally, including Utah.

• Is there an exercise oncology or cancer rehabilitation program here I can be referred to?
• Are there any activity restrictions I should know about given my surgery, my current treatment, or my bone health?
• What signs should make me stop exercising and call the clinic?
• Would a physical therapist or certified exercise oncologist be helpful for me?

• Dietary fiber: Multiple observational studies and meta-analyses link higher fiber intake with lower CRC risk. After diagnosis, high-fiber diets appear protective. Sources: whole grains, legumes (beans, lentils), vegetables, fruit. Target: 25–35 g/day where bowel function permits (reduced after right-sided resection or ileostomy).
• Mediterranean dietary pattern: Associated with lower all-cause and cancer-specific mortality in CRC survivors in pooled analyses. Core elements: olive oil as primary fat, abundant vegetables and fruit, whole grains, legumes, nuts, fish 2–3×/week, minimal red/processed meat, moderate dairy.
• Calcium and vitamin D: Calcium intake (food sources preferred: dairy, fortified foods) is associated with modestly reduced colorectal cancer risk in large cohort studies. Vitamin D adequacy is recommended; formal supplementation for cancer recurrence prevention remains under study (SUNSHINE trial showed a non-significant trend toward improved survival with high-dose vitamin D3 in mCRC). Ask your oncologist about checking vitamin D levels.
• Coffee: Moderate coffee consumption (2–4 cups/day) is consistently associated with lower CRC risk in meta-analyses and may reduce recurrence risk. The association appears to apply to both caffeinated and decaffeinated coffee.
• Weight management: Overweight and obesity are associated with increased CRC risk and worse outcomes. Even modest weight loss (5–10% of body weight) in patients who are overweight improves insulin sensitivity and reduces circulating pro-cancer growth factors. Intentional weight loss is appropriate for most overweight CRC survivors.

• Red and processed meat: The WHO classifies processed meat as a Group 1 carcinogen for colorectal cancer. Red meat is Group 2A. Processed meat (bacon, sausage, hot dogs, deli meats, salami) carries the strongest association. Limit processed meat consumption after diagnosis; if red meat is consumed, limit to <18 oz (cooked weight) per week (WCRF/ACS guidance).
• Alcohol: Alcohol is a Group 1 carcinogen for colorectal cancer. Even modest alcohol intake increases risk. For patients already diagnosed, minimizing or eliminating alcohol is a reasonable evidence-based goal. Some chemotherapy drugs (including certain targeted agents) interact with alcohol.
• Ultra-processed foods and refined carbohydrates: High-glycemic dietary patterns and ultra-processed food consumption are associated with higher CRC risk and worse outcomes in survivorship cohorts.
• Sedentary dietary patterns (Western diet): High in red/processed meat, refined grains, added sugars, and low in vegetables — consistently linked to worse CRC outcomes.

• Right-sided colectomy often causes loose stools and shorter bowel transit. High-fiber foods may need to be introduced gradually. Work with an oncology dietitian for the first 2–3 months post-surgery.
• Patients with a colostomy or ileostomy have specific dietary considerations: certain high-gas foods (beans, broccoli, cabbage), high-fiber foods, and thick/stringy foods may need modification. Colostomy nurses and oncology dietitians at the treating center can provide individualized guidance.
• Oxaliplatin causes cold sensitivity (not just neuropathy) — cold liquids and foods can trigger acute painful dysesthesias. During active oxaliplatin treatment, room-temperature or warm foods and beverages are generally better tolerated.
• Nausea during chemotherapy is best managed with small frequent meals, bland easy-to-digest foods, and staying well hydrated. Ginger (real ginger, not ginger-flavored) has modest evidence for chemotherapy nausea.

For personalized dietary guidance, ask for a referral to a registered dietitian (RD) with oncology experience. Huntsman Cancer Institute, MD Anderson, and most NCI-designated cancer centers have oncology dietitians available to patients.

• Can I be referred to an oncology dietitian for individualized guidance?
• Is my weight or nutritional status a concern given my treatment plan?
• Should I take any supplements — vitamin D, calcium, probiotics? Are there any supplements I should specifically avoid during chemotherapy?
• Are there dietary changes that could interact with my specific medications (for example, grapefruit with some targeted agents)?
• What are the best foods to prioritize for reducing recurrence risk once I finish active treatment?

After part of the colon is removed, bowel habits usually change for a time. Looser, more frequent, or more urgent stools are common, particularly after right-sided resections, and typically improve over weeks to months as the bowel adapts. Practical steps include eating smaller and more regular meals, staying hydrated, identifying trigger foods, and using medications as the team advises. Persistent or severe changes should be reported — an oncology dietitian can help considerably.

• Nausea: Usually well controlled with anti-nausea medication taken on schedule. Tell the team if it is not controlled — the regimen can be strengthened.
• Fatigue: The most common side effect. Light regular activity helps more than rest alone.
• Diarrhea: Especially with irinotecan-based regimens. Should be managed promptly; significant diarrhea with fever or dehydration needs same-day contact.
• Hand-foot syndrome: With capecitabine — soreness and redness of palms and soles. Managed with moisturizers, avoiding friction and heat, and dose adjustment if needed.
• Low blood counts: Raise the risk of infection and bleeding. A fever during chemotherapy can be a medical emergency.

Palliative care is specialized care focused on relieving symptoms and improving quality of life. It can and should run alongside active, curative-intent treatment from the beginning. It is not the same as hospice. Studies have shown that early palliative care improves quality of life and, in some settings, even survival — partly because patients who feel better tolerate more treatment.

Hospice is a distinct, comfort-focused kind of care for patients in the final months of life who choose to focus on quality of time rather than active anti-cancer treatment. It is covered by Medicare and provides deep support for patients and families.

After curative treatment, structured surveillance catches recurrence early — when it may still be curable. The standard elements for stage II–III colon cancer include:

• CEA blood test: Every 3–6 months for about 2 years, then every 6 months through year 5.
• CT of chest, abdomen, and pelvis: Typically yearly for about 5 years (more often for higher-risk patients).
• Surveillance colonoscopy: About 1 year after surgery. If clear, the next is usually in 3 years, then every 5 years. Patients with Lynch syndrome typically need annual colonoscopy.
• Regular clinic visits to review symptoms, examination, and results.

Ask the oncology team for a written survivorship care plan that lays out the schedule and who is responsible for each part.

Colon cancer in younger adults (under 50) is rising, and questions about fertility and family planning are increasingly common. This is a conversation to have before treatment begins, when options are widest.

• Fertility preservation before chemotherapy: Fluoropyrimidine-based chemotherapy (FOLFOX, CAPOX) carries a risk of gonadal toxicity, especially with higher cumulative doses and in patients who receive pelvic radiation (for rectal cancer). Before starting treatment, ask for an urgent referral to a reproductive endocrinologist. Embryo or egg freezing (oocyte cryopreservation) can typically be completed within 2–3 weeks and does not meaningfully delay oncologic treatment. Sperm banking for men is straightforward and should be offered routinely. Most major academic cancer centers (including Huntsman Cancer Institute) have on-site or closely affiliated fertility preservation programs.
• Which chemotherapy drugs affect fertility: Oxaliplatin has some evidence of gonadal toxicity but is generally less of a concern than alkylating agents. Irinotecan may affect sperm quality. Bevacizumab is teratogenic and must not be used during pregnancy. Anti-EGFR agents (cetuximab, panitumumab) and targeted therapies are also generally contraindicated in pregnancy. Immunotherapy (pembrolizumab, nivolumab) is contraindicated in pregnancy.
• Timing pregnancy after treatment: Most oncologists recommend waiting at least 6 months after completing chemotherapy before attempting pregnancy, though practices vary. For stage III disease, many recommend waiting 2–3 years (the highest recurrence-risk period) before pregnancy, to allow complete surveillance without pregnancy complicating follow-up imaging (CT scans involve radiation). Discuss this timing with both the oncologist and the obstetrician-gynecologist, ideally before starting treatment.
• Lynch syndrome and family planning: For patients with Lynch syndrome, cascade testing of first-degree relatives is important — they have a 50% chance of inheriting the germline mutation. Preimplantation genetic testing (PGT) is available for Lynch syndrome carriers who wish to avoid passing the mutation to children conceived through IVF.
• Pregnancy during treatment: If a patient is pregnant at diagnosis, a multidisciplinary team including maternal-fetal medicine, medical oncology, and surgical oncology must coordinate care. Colon cancer surgery can generally be performed safely in pregnancy. Chemotherapy can be considered in the second and third trimester in selected cases. First-trimester chemotherapy carries the highest risk of fetal harm.
• Resources: Fertile Hope / LIVESTRONG Fertility (livestrong.org/fertility) — financial assistance for fertility preservation for cancer patients. Resolve: The National Infertility Association (resolve.org). Huntsman Cancer Institute: 801-587-7000 (ask to be connected with reproductive oncology resources).

Colon cancer treatment can affect sexual health and body image in several ways that are rarely discussed proactively. These are legitimate medical issues, not vanity concerns, and they are treatable.

• After surgery: Fatigue and wound healing initially limit activity. Body image concerns are common, especially for patients with a stoma (colostomy or ileostomy). Wound/ostomy nurses can provide practical guidance on intimate activity with an ostomy appliance, including tips on pouch security and discretion.
• Neuropathy and intimacy: Peripheral neuropathy from oxaliplatin can affect sensation. This typically improves after completing chemotherapy, though for some patients it persists.
• Pelvic floor and rectal cancer: Rectal cancer surgery and radiation can affect bladder and sexual function in both men (erectile dysfunction, ejaculatory changes) and women (vaginal dryness, dyspareunia). Pelvic floor physical therapy can help significantly. Ask for a referral.
• Asking for help: Many patients are reluctant to raise sexual health concerns. The team cannot help if they don't know. A direct question to a nurse, social worker, or physician — "Has my treatment affected sexual function, and what can be done?" — typically opens the conversation. Many centers have specialists in oncology sexual health.

Surveillance aims to catch recurrence early, when it is most treatable. NCCN and ESMO guidelines converge on similar schedules. The most important thing is that patients know what tests are needed and ensure they are being ordered — surveillance gaps are unfortunately common.

Oxaliplatin neuropathy is one of the most common long-term effects of adjuvant or palliative FOLFOX or CAPOX chemotherapy. It affects the nerve endings in the hands and feet (peripheral neuropathy) and can range from mild and temporary to severe and persistent.

What it feels like:

• Tingling, numbness, or “pins and needles” in fingers and toes (most common)
• Cold sensitivity: a sharp, electric-shock sensation when touching cold objects or breathing cold air during treatment (this is the acute form, usually temporary)
• Burning or shooting pain (less common)
• Difficulty with fine motor tasks: buttons, zippers, typing, handling coins
• Balance problems and risk of falls, especially in the dark

What to do:

• Tell your care team at every visit. Neuropathy worsens with cumulative oxaliplatin dose. Grade 2 (affecting daily activities) warrants dose reduction. Grade 3 (severe, limiting self-care) warrants permanent discontinuation. It is dangerous to “push through” worsening neuropathy.
• Duloxetine: An antidepressant with evidence for reducing oxaliplatin-induced neuropathy pain. A randomized clinical trial showed it significantly reduced pain in established neuropathy. Often started at 30 mg/day and titrated to 60 mg/day. Takes 2–4 weeks for full effect.
• Cold avoidance during treatment: Wear gloves when reaching into freezer or handling cold items. Cold-sensitivity is acute and not the same as long-term neuropathy.
• Occupational therapy: For patients with significant hand function impairment, occupational therapy provides adaptive tools and exercises.
• Timeline: Mild-to-moderate neuropathy often improves over 6–18 months after chemotherapy ends. Severe Grade 3 neuropathy may be permanent or only partially resolve. The “stop-and-go” approach (stopping oxaliplatin after 3 months and restarting if disease progresses) reduces cumulative neurotoxicity without compromising cancer outcomes.

A permanent colostomy is life-changing but not life-limiting. Hundreds of thousands of people worldwide live full, active, and satisfying lives with a colostomy — they swim, travel, run marathons, maintain romantic relationships, and work demanding jobs. The adjustment is real and takes time, but with the right support, most people find a comfortable routine.

Practical management:

• WOC (wound, ostomy, and continence) nurse: Your single most important resource. A certified WOC nurse teaches proper appliance fitting, skin care, and troubleshooting. Request this referral before surgery for optimal stoma site placement, and again immediately post-operatively. Most insurance plans cover these appointments.
• Appliance selection: The first appliance prescribed in hospital may not be the one you use permanently. Several systems exist (one-piece, two-piece, drainable, closed). Trial and adjustment over the first few months — guided by your WOC nurse — usually leads to a system that works well for your anatomy and lifestyle.
• Irrigation (for sigmoid colostomy only): Some patients with sigmoid colostomies can use a daily irrigation technique to regulate output, allowing them to go without an appliance pouch during the day. This requires training and is not for everyone, but can dramatically improve quality of life. Discuss with your WOC nurse.
• Parastomal hernia: Bulging around the stoma site due to abdominal wall weakness. Very common (30–50% of colostomy patients over time). Prevention: supportive abdominal belts post-operatively; avoiding heavy lifting while healing. Repair: surgery if symptoms are severe (obstruction, skin problems, appliance fitting failure).

Lifestyle:

• Diet: No specific foods are prohibited, but some cause odor or gas changes (beans, cruciferous vegetables, beer). Individual variation is significant. A structured food diary during the first few months helps identify personal triggers.
• Swimming and exercise: Waterproof ostomy covers and caps allow swimming. All forms of exercise are possible with appropriate support belts for impact activities.
• Travel: Carry twice the necessary supplies, distributed across carry-on and checked luggage. TSA/airport procedures for ostomy patients: you may request a private screening. MedicAlert-type cards explaining the ostomy are available from ostomy advocacy organizations.
• Intimacy and relationships: Sexual and intimate relationships can absolutely continue post-colostomy. Open communication with a partner, and connection with a sexual health counselor or therapist familiar with cancer survivorship, can help navigate this aspect of adjustment.

Resource: United Ostomy Associations of America (UOAA): www.ostomy.org. Peer visitor programs match patients who have newly received a colostomy with experienced ostomy patients for practical, lived-experience support.

Colorectal cancer treatment — particularly pelvic surgery and pelvic radiation for rectal cancer — can significantly affect sexual function in both men and women. This is a topic many patients feel reluctant to raise with their care team. Raise it anyway. Effective interventions exist.

In men:

• Erectile dysfunction: Pelvic surgery (especially APR and low LAR) can injure the autonomic nerves that control erection. Risk depends on nerve preservation during surgery. Erectile dysfunction affects 30–50% of men after pelvic colorectal surgery; higher rates with APR.
• Ejaculatory disorders: Retrograde ejaculation and dry orgasm are common after pelvic nerve damage. Sensation and orgasm are often preserved even when ejaculation is affected.
• Treatment options: PDE5 inhibitors (sildenafil/tadalafil) are effective for neurogenic ED; penile rehabilitation (starting early, even before erections return) improves long-term outcomes. Vacuum erection devices, penile injections (alprostadil), and penile prosthesis implant are options for refractory cases. Referral to a urologist with sexual medicine expertise is recommended if dysfunction persists beyond 3–6 months.

In women:

• Vaginal dryness and dyspareunia: Pelvic radiation and pelvic surgery can narrow the vagina (vaginal stenosis) and reduce natural lubrication. Vaginal dilators (used starting 2–4 weeks after radiation) prevent stricture. Vaginal estrogen (local, minimal systemic absorption) is safe for most CRC survivors and significantly improves lubrication and elasticity.
• Orgasm and arousal: Pelvic nerve damage can affect arousal response and reduce sensitivity. Vibrators and arousal aids can be helpful. Sexual medicine or pelvic floor physical therapy referrals are appropriate.
• Fertility after treatment: If the patient is of reproductive age, the effects of chemotherapy (gonadotoxicity) and pelvic radiation (ovarian damage, uterine damage) on future fertility should have been discussed before treatment. For patients who did not have this discussion, a reproductive endocrinology consultation can assess current fertility status. Egg or embryo freezing should ideally occur before chemotherapy; it is not impossible after treatment but may be more difficult.

While no single food or supplement is proven to prevent colon cancer recurrence, strong evidence supports dietary patterns that influence colon cancer risk and overall survival. The goal after treatment is a health-promoting diet that supports immune function, healthy weight, and bowel recovery.

Evidence-based dietary guidance:

• Dietary fiber: Higher fiber intake (25–35 g/day from vegetables, fruits, legumes, and whole grains) is associated with lower colon cancer risk in population studies. After surgery, fiber can improve bowel regularity and reduce constipation.
• Western diet (red/processed meat, refined carbohydrates, added sugars): The WCRF2 Western dietary pattern is associated with significantly worse colon cancer recurrence rates and survival in multiple cohort studies. Reducing processed meat, red meat (<3 servings/week), and ultra-processed foods is recommended.
• Mediterranean/DASH pattern: Olive oil, whole grains, fish, legumes, abundant vegetables and fruit — associated with reduced CRC recurrence risk and better overall cardiovascular health (relevant given treatment-related cardiac risks).
• Alcohol: Alcohol is a confirmed colon cancer risk factor. The World Cancer Research Fund recommends no more than one drink per day for cancer survivors, and abstaining may be safer for high-risk patients.
• Vitamin D: Vitamin D deficiency is extremely common in CRC patients and associated with worse outcomes in observational studies. An RCT (SUNSHINE) showed no significant OS benefit from high-dose vitamin D supplementation, but correction of vitamin D deficiency is still prudent. Check 25-OH vitamin D at baseline; maintain level ≥40 ng/mL with supplementation if deficient.
• Omega-3 fatty acids (fish oil): Pre-clinical and epidemiological data are promising; no large RCTs specifically in CRC survivors. Reasonable to include fatty fish (salmon, sardines, mackerel) 2–3 times per week.

What to avoid: High-dose antioxidant supplements during chemotherapy or radiation — theoretical concern for reducing treatment effectiveness (mixed evidence, but most oncology dietitians recommend avoiding megadose antioxidant supplements during active treatment). This is separate from food-derived antioxidants, which are safe and encouraged.

Resource: Ask your cancer center for a referral to a registered dietitian with oncology training. Many cancer centers have dedicated oncology dietitians who specialize in post-treatment nutritional support.

Colon cancer treatment unfolds over months. Caregivers are typically the most stretched people in the household, and caregiver burnout is real. Key strategies:

• Build a team, not a single hero. Even with one primary caregiver, others should rotate in. Scheduled time off for the primary caregiver is maintenance, not luxury.
• Set up help early — meal trains, rides, household help, childcare — before a hard stretch arrives.
• Use coordination platforms like CaringBridge (caringbridge.org) or Lotsa Helping Hands to keep the broader circle informed and organized.
• Use caregiver resources: Family Caregiver Alliance (caregiver.org, 800-445-8106) and cancer center caregiver support groups.

Children do better with honest, age-appropriate information than with attempts to shield them entirely — they sense something is wrong and often imagine worse than the truth. CancerCare (cancercare.org, 800-813-4673) and the American Cancer Society have resources and counselors for talking with children. Many cancer centers have child-life specialists or family counselors.

Anxiety, fear, and low mood are normal responses to a cancer diagnosis, not weakness, and they are treatable. Resources include oncology social workers and psychologists, medication when appropriate, support groups, mindfulness programs, and spiritual or religious community. Asking for a referral to supportive oncology or psycho-oncology services is a sign of good self-care.

Some practical preparation is wise for any serious illness and is best done early. Depending on the situation, this may include reviewing or creating a will, establishing durable power of attorney for healthcare and finances, creating an advance directive, and making sure beneficiary designations are current. An estate-planning attorney can complete most of this in a single appointment. Doing it early means it does not have to be done in a crisis.

Honest hope is not the same as optimism. Optimism says “this will be fine.” Honest hope says “we will do everything reasonable, make decisions with full information, and face whatever comes with the people we love.” For most colon cancer patients, that honest hope is also genuinely well-founded — because the most common situations carry real and often excellent chances of cure.

• Stage I (roughly 90%+ five-year survival): Usually cured by surgery alone. The outlook is excellent.
• Stage II (roughly 80–85%): Most patients are cured by surgery, sometimes with adjuvant chemotherapy. The outlook is very good.
• Stage III (roughly 60–80%, depending on sub-stage): A serious diagnosis, but the majority are cured with surgery plus adjuvant therapy. The treatment is demanding but worthwhile.
• Stage IV (roughly 15% overall — but far higher for resectable disease): The hardest situation, but the one where modern treatment has changed the most. Patients with removable metastases can be cured; many others live for years with good quality of life.

Remember: these are averages that blend many different situations, and they lag behind current treatment. A patient treated today generally does better than figures based on earlier treatment suggest.

• Let the patient lead the depth of the conversation. Some patients want to discuss everything explicitly; others prefer to focus on the day-to-day. Both are valid.
• Do not avoid hard conversations because they are hard. Most people describe regret over things left unsaid, rarely over conversations they did have.
• Talk about what matters most — what the patient wants to do with their time, what they want to say, what they want remembered.
• Keep living. The point of preparation and organization is to free the family to be present with the patient.

For some patients, the conversation eventually turns toward a shift in focus — from treatment aimed at controlling the cancer to care aimed at comfort and quality of remaining time. Choosing hospice is not “giving up” — it is a recognition of what the disease is doing and a decision about how to spend the time that remains. Some patients on hospice live longer than expected. The hospice team becomes a profound source of support for both patient and family.

1. Get the complete picture before treatment is locked in. Confirm diagnosis, complete staging, and ensure mismatch repair / MSI testing is ordered (with a full molecular panel for metastatic disease). The plan should not be finalized without at least the MSI result.
2. Get a complete, high-quality surgery at an experienced center. Confirm the surgeon has real colorectal cancer experience. After surgery, confirm clear margins and at least 12 lymph nodes examined.
3. Make the adjuvant-therapy decision well, and on time. For stage III and high-risk stage II, work through the decision using stage, adverse features, MSI status, and patient factors. For stage III dMMR disease, ask about atezolizumab. Aim to start within 6–8 weeks of surgery.
4. For metastatic disease, ask the resectability question first. Get a multidisciplinary review including a metastasis surgeon. Match first-line treatment to the molecular profile.
5. Address Lynch syndrome and the family. If the tumor is dMMR/MSI-high, the patient was diagnosed young, or there is a family history, request genetic counseling and germline testing.
6. Treat clinical trials as a real option, not a last resort. Ask the treating center what is open. For dMMR localized disease, ask about neoadjuvant immunotherapy trials.
7. Get a well-chosen second opinion if the situation warrants it. Particularly for stage IV, recurrent disease, uncommon molecular features, or complex surgical questions.
8. Build the supportive foundation. Engage palliative/supportive care early. Report neuropathy and side effects promptly. See an oncology dietitian. Build a structured exercise habit — it has trial-level evidence for reducing recurrence.

• What is the exact diagnosis, and what stage do you believe this is so far?
• Has the entire colon been examined?
• What staging tests are being done, and when will results be back?
• Has mismatch repair / MSI testing been ordered? For metastatic disease, has a full molecular panel been ordered?
• Is this a center with a dedicated colorectal or GI cancer program? Will my case be discussed at a multidisciplinary tumor board?
• Should we consider genetic counseling given my age and family history?
• Is there time for a second opinion?

• What operation are you recommending, and why? Will it be minimally invasive or open?
• Based on tumor location, do you expect I will need an ostomy — temporary or permanent?
• How many colon cancer operations do you perform per year?
• After surgery: What did the final pathology show — stage, grade, margins?
• How many lymph nodes were examined, and how many contained cancer?
• Is there preserved tumor tissue available for additional molecular testing later?

• Based on the final pathology, do you recommend adjuvant chemotherapy? What is the estimated reduction in recurrence risk, in numbers?
• Which regimen — an oxaliplatin doublet or a single agent — and why, given my age and health?
• Where does my cancer fall on the IDEA risk groups — is three months or six months recommended?
• Is my tumor dMMR / MSI-high? If so, should atezolizumab be added?
• What side effects should I expect, and what is the plan if neuropathy develops?
• When should treatment start, and is a port recommended?
• Is ctDNA testing appropriate in my case?

• Are the metastases removable by surgery — now, or potentially after treatment? Has a metastasis surgeon reviewed my case?
• Is the full molecular profile back? Does it point to immunotherapy or a targeted therapy?
• What is the goal of first-line treatment — cure, or long-term control?
• What clinical trials might I be eligible for?
• How will we know if treatment is working, and how often will I be scanned?

• Honestly, given my specific stage and tumor biology, what is the realistic range of outcomes?
• Beyond receiving treatment, what have you seen patients do that actually makes a difference?
• What is the most useful thing my family can do to support me?
• How and when do we revisit the plan? How do I reach the team between visits?

• The treating center’s financial counseling office. At Huntsman, a patient financial advocate is assigned to new patients (801-587-7000). They help with insurance navigation, copay assistance, and payment plans. Engage them early.
• The oncology social worker. Most cancer centers have social workers who connect families to assistance, transportation, and lodging resources.

• Patient Advocate Foundation — case management and copay relief. 800-532-5274. patientadvocate.org
• CancerCare — financial-assistance grants, counseling, education. 800-813-4673. cancercare.org
• HealthWell Foundation — copay assistance for specific drugs. 800-675-8416. healthwellfoundation.org
• PAN Foundation — copay assistance. 866-316-7263. panfoundation.org
• Family Reach — emergency financial help (rent, utilities, transportation). familyreach.org
• NeedyMeds — database of prescription-assistance programs. 800-503-6897. needymeds.org

• Colorectal Cancer Alliance — financial assistance, helpline, patient navigation. 877-422-2030. ccalliance.org
• Fight Colorectal Cancer — patient resources, financial guides, advocacy. fightcrc.org
• United Ostomy Associations of America — education, support groups, peer support. ostomy.org

• Social Security Disability Insurance (SSDI) — 800-772-1213. ssa.gov. Certain advanced cancers qualify for expedited review.
• Medicare — 800-633-4227. medicare.gov
• Medicaid (Utah) — medicaid.utah.gov; 1-866-435-7414
• FMLA — job-protected leave for patient and family caregivers; apply through employer.
• American Cancer Society — lodging (Hope Lodge), 24/7 help line. 800-227-2345. cancer.org
• Mercy Medical Angels — ground and air transportation. mercymedical.org
• Joe’s House — lodging assistance for treatment travel. joeshouse.org

• First 1–3 weeks: Diagnosis confirmed; staging workup done; MSI testing ordered (full panel if metastatic); treating center and surgeon identified; records gathered; second opinion and genetic counseling considered.
• Surgery and recovery: Operation done; pathology reviewed (stage, margins, ≥12 nodes); molecular results back; enhanced recovery followed; adjuvant timeline in view.
• Weeks 4–8 after surgery: Adjuvant decision made; for stage III dMMR, atezolizumab discussed; chemotherapy begins within this window.
• Adjuvant treatment period: Treatment underway; side effects (especially neuropathy) reported; supportive care and exercise established.
• Metastatic disease: Multidisciplinary review with metastasis surgeon; resectability determined; molecular profile confirmed; first-line matched to biology; trials considered; palliative care engaged.
• After curative treatment: Structured surveillance (CEA, CT, colonoscopy); written survivorship plan; long-term effects addressed.

• Fever during chemotherapy (100.4°F / 38°C or higher with low blood counts) — can be life-threatening infection. Contact the team or go to the ER the same day.
• Severe diarrhea, vomiting, or dehydration during treatment — contact the team the same day.
• Severe abdominal pain, inability to pass stool or gas, persistent vomiting — can signal bowel obstruction. Seek prompt medical attention.
• One-sided leg swelling, sudden shortness of breath, or chest pain — may indicate a blood clot. Call 911 or go to the ER.
• New or worsening neuropathy — report at or before the next visit so the oxaliplatin dose can be adjusted.
• Rising CEA or new finding on surveillance scan — request a copy and ask the team within a few days.
• Recurrence confirmed — request complete restaging, molecular re-testing, and a multidisciplinary review. Consider a second opinion and clinical trials.

• Exactly who benefits from adjuvant chemotherapy in stage II disease, and how much, remains an area of real debate — which is why ctDNA is being studied to sharpen the answer.
• How best to use ctDNA — to guide adjuvant therapy, monitor for recurrence, and act on rising levels — is still being worked out. It is a promising tool, not yet a settled one.
• How to make immunotherapy work for mismatch-repair-proficient tumors — the large majority of colon cancers — is one of the central unsolved problems and a major focus of clinical trials.
• The optimal role of neoadjuvant immunotherapy in localized dMMR disease, including whether some patients might safely avoid surgery, is an active research question.
• Why colon cancer is rising in younger adults is not understood. Research is ongoing.

It is not uncertain that a complete, high-quality surgery is the foundation of cure for localized colon cancer. It is not uncertain that adequate lymph node evaluation matters, that molecular testing changes treatment for the better, that timely adjuvant therapy reduces recurrence in stage III disease, that immunotherapy transforms outcomes in dMMR disease, or that experienced multidisciplinary centers achieve better results. It is not uncertain that most colon cancer caught before distant spread is curable — or that even advanced disease is far more treatable than it was a generation ago. These facts are the foundation this guide rests on, and they are the reason for genuine, clear-eyed hope.

Liquid biopsy tests that detect circulating tumor DNA (ctDNA) after surgery can identify patients with residual microscopic disease 8–12 months before it appears on CT scans. This is an extraordinary early-warning capability. But detecting a problem earlier is only useful if acting on it earlier leads to better outcomes — and that is what remains unproven.

The DYNAMIC trial showed ctDNA can safely de-escalate adjuvant chemotherapy (sparing ctDNA-negative patients the treatment and its side effects without harming outcomes). The DYNAMIC-III and CIRCULATE-Japan trials are testing whether ctDNA-positive patients who receive earlier intervention do better. Until those results are available — expected in the late 2020s — the evidence for using ctDNA to intensify treatment (rather than to de-escalate it) is not established. Patients who receive ctDNA testing showing a positive result should be enrolled in a clinical trial or discussed in a multidisciplinary tumor board, not reflexively started on chemotherapy outside of a protocol.

Specific gut bacteria — particularly Fusobacterium nucleatum and Bacteroides fragilis — are found at elevated levels in colon cancer tumor tissue and have been associated with worse outcomes in some studies. Whether these bacteria cause cancer to grow, or simply colonize cancer tissue preferentially, has not been established. Manipulating the microbiome through probiotics, fecal transplant, or dietary changes to improve cancer outcomes is under active investigation, but is not ready for clinical practice recommendations.

The interventions most clearly associated with a favorable microbiome profile — high-fiber diet, regular exercise, limiting ultra-processed foods, avoiding unnecessary antibiotics — overlap precisely with lifestyle recommendations supported by independent evidence. Probiotic supplements marketed specifically for cancer survivors have not been proven to reduce recurrence and are not standard of care.

Colon cancer in adults under 50 is increasing at about 2% per year. In adults under 35, the increase is faster still. This has happened across multiple countries simultaneously, pointing to a widespread exposure change — but the cause is not known.

Factors under investigation: changes in gut microbiome (related to antibiotic use, processed food, cesarean birth rates, formula feeding); ultra-processed food consumption; obesity; sedentary behavior beginning in childhood; environmental exposures; reduced dietary fiber. No single cause has been confirmed, and the increase is likely multi-factorial.

What this means for patients diagnosed under 50: germline genetic testing is strongly recommended for all (approximately 16–20% will carry a pathogenic inherited variant); family members should be offered early colonoscopy; and the tumor biology of early-onset CRC has distinct features that may eventually require specific treatment algorithms — though current treatment is the same as for older patients with the same stage and molecular profile.

The FDA has approved the broadest range of targeted and immunotherapy agents for colorectal cancer. Key approvals include:

• Pembrolizumab (Keytruda) — first-line for dMMR/MSI-H metastatic CRC (KEYNOTE-177; FDA approved June 2020)
• Nivolumab + ipilimumab (Opdivo + Yervoy) — dMMR/MSI-H mCRC (CheckMate 8HW; FDA approved April 2024)
• Encorafenib + cetuximab (Braftovi + Erbitux) — BRAF V600E-mutant mCRC; second/third-line since April 2020 (BEACON CRC); first-line approval February 24, 2026 via the BREAKWATER trial
• Tucatinib + trastuzumab (Tukysa + Herceptin) — HER2-positive RAS wild-type mCRC (MOUNTAINEER; FDA approved January 2023)
• Sotorasib + panitumumab (Lumakras + Vectibix) — KRAS G12C-mutant mCRC (CodeBreaK 300; FDA approved January 16, 2025)
• Adagrasib + cetuximab (Krazati + Erbitux) — KRAS G12C-mutant mCRC (KRYSTAL-10; FDA accelerated approval June 2024)
• Fruquintinib (Fruzaqla) — refractory mCRC (FRESCO-2; FDA approved November 8, 2023)
• Trifluridine/tipiracil (Lonsurf) and regorafenib (Stivarga) — later-line mCRC

NCCN Guidelines (National Comprehensive Cancer Network, nccn.org) are the primary US clinical reference and are updated multiple times per year. DPYD testing before fluoropyrimidine therapy is recommended but not yet federally mandated.

If you are being treated in the US, ask your team: “Are you following the most current NCCN guidelines? Have I had all recommended molecular tests, including MSI/MMR, KRAS/NRAS/BRAF, HER2, and DPYD?”

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) grants market authorization. Access on the NHS is then determined by NICE (National Institute for Health and Care Excellence) technology appraisals. Not all MHRA-approved drugs receive NICE recommendation due to cost-effectiveness thresholds.

Key NICE technology appraisals for colorectal cancer:

• TA668 — Encorafenib + cetuximab (Braftovi + Erbitux) for BRAF V600E-mutant mCRC, previously treated (January 2021): recommended
• TA716 — Nivolumab + ipilimumab (Opdivo + Yervoy) for dMMR/MSI-H mCRC, second-line and beyond (July 2021): recommended
• TA818 — Pembrolizumab (Keytruda) for dMMR/MSI-H mCRC, first-line (July 2023): recommended
• New TA (April 2025) — Nivolumab + ipilimumab for dMMR/MSI-H mCRC, first-line (CheckMate 8HW): recommended
• Fruquintinib (Fruzaqla): MHRA approval September 2024; NICE appraisal in progress as of mid-2026 — not yet recommended on NHS routine commissioning
• Encorafenib + cetuximab first-line (BRAF V600E, BREAKWATER): NICE appraisal in progress as of mid-2026
• Adagrasib + cetuximab (KRAS G12C): NICE appraisal pending

Cancer Drugs Fund (CDF): When NICE cannot yet make a final recommendation, some drugs are available through the CDF — an interim access mechanism funded by NHS England while longer-term data are collected. Ask your oncologist whether any drug you need is in the CDF.

DPYD testing: The NHS Genomics Medicine Service mandated DPYD genotyping before fluoropyrimidine treatment in 2020 — one of the first countries globally to require this. All NHS patients starting capecitabine or 5-FU must be tested.

Named specialist centers:

• The Christie Hospital NHS Foundation Trust (Manchester) — largest single-site cancer center in Europe; comprehensive colorectal program — +44-161-446-3000
• The Royal Marsden NHS Foundation Trust (London / Surrey) — leading UK cancer center, strong GI oncology program — +44-20-8642-6011
• University College London Hospitals (UCLH) (London) — NCI-designated equivalent, molecular tumor board — +44-20-3456-7890
• The Beatson West of Scotland Cancer Centre (Glasgow) — primary specialist center for Scotland — +44-141-301-7000
• Leeds Cancer Centre, St. James’s University Hospital (Leeds) — major regional center serving northern England — +44-113-206-6400

If you are being treated in the UK, ask: “Is this drug covered by NICE or the Cancer Drugs Fund? Has my team submitted a CDF application if needed?”

The European Medicines Agency (EMA) grants EU-wide marketing authorization; national agencies (ANSM in France, AIFA in Italy, BfArM in Germany, AEMPS in Spain) then manage reimbursement. ESMO (European Society for Medical Oncology) guidelines are the primary pan-European clinical reference, updated annually, and broadly aligned with NCCN with some important differences:

• Anti-EGFR sidedness: ESMO more explicitly restricts cetuximab and panitumumab to left-sided primary tumors in first-line therapy. NCCN acknowledges the data but leaves more clinical judgment. In practice, right-sided tumors rarely benefit from anti-EGFR therapy regardless of guidelines.
• DPYD testing: The EMA mandated DPYD genotyping before all fluoropyrimidine (5-FU, capecitabine) treatment in 2020 — mandatory across all EU member states. This is one area where Europe is ahead of the US.
• Fruquintinib (Fruzaqla): EMA approval July 2024. National reimbursement varies: under review in Italy (AIFA), Germany (G-BA), and other member states as of mid-2026.
• BREAKWATER first-line encorafenib + cetuximab: Currently under EMA review for first-line BRAF V600E indication (approved only for previously treated patients in the EU as of mid-2026).

Germany operates under the AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) system: drugs approved by the EMA are available, and the Federal Joint Committee (G-BA) evaluates their added benefit for GKV (statutory health insurance) reimbursement. Most targeted oncology agents receive reimbursement, though negotiated prices vary.

AWMF S3-Leitlinie Kolorektales Karzinom (S3-LL KRK): Updated 2023/2024, this is the primary German clinical guideline and closely aligns with ESMO and NCCN recommendations.

DPYD testing: The BfArM (Federal Institute for Drugs and Medical Devices) made DPYD testing mandatory before fluoropyrimidine therapy in 2020, matching the EU-wide EMA requirement.

Named specialist centers (Comprehensive Cancer Centers, certified by Deutsche Krebsgesellschaft):

• Charité Comprehensive Cancer Center (Berlin) — one of Europe’s largest university hospitals; certified Darmkrebszentrum — +49-30-450-564-222
• National Center for Tumor Diseases (NCT) / DKFZ Heidelberg (Heidelberg) — Germany’s leading cancer research center; broad molecular profiling — +49-6221-56-36000
• University Medical Center Hamburg-Eppendorf (UKE) (Hamburg) — major CRC surgical and oncology program — +49-40-7410-0
• Munich Comprehensive Cancer Center (MCCC / LMU + TU Munich) (Munich) — integrated cancer center across two major university hospitals — +49-89-4400-72730
• University Hospital Cologne (Uniklinik Köln) (Cologne) — certified Darmkrebszentrum, active in CRC clinical trials — +49-221-478-0

If you are being treated in Germany, ask about your tumor profile for targeted therapies. Most German centers offer English-speaking oncologists.

In France, the ANSM (Agence nationale de sécurité du médicament) grants market authorization within the EMA framework. The HAS (Haute Autorité de Santé) evaluates drugs for reimbursement through the national health insurance system (Sécurité Sociale). INCa (Institut National du Cancer) publishes national cancer guidelines, which align closely with ESMO and NCCN.

DPYD testing: ANSM mandated DPYD genotyping before fluoropyrimidine treatment in October 2020 — one of the first regulatory bodies globally to require this. All patients starting capecitabine or 5-FU must be tested; the test is covered by the national health system.

Named specialist centers (CLCC — Centres de Lutte Contre le Cancer, certified comprehensive cancer centers):

• Institut Gustave Roussy (Villejuif, near Paris) — largest cancer center in Europe; comprehensive GI oncology program, extensive clinical trials — +33-1-42-11-42-11
• Institut Paoli-Calmettes (Marseille) — CLCC for the Mediterranean region; molecular tumor board — +33-4-91-22-33-33
• Centre Léon Bérard (Lyon) — CLCC for the Auvergne-Rhône-Alpes region; active in CRC immunotherapy trials — +33-4-78-78-26-57
• Institut Curie (Paris) — major comprehensive cancer center; GI oncology expertise; international patient services — +33-1-56-24-55-55

If you are being treated in France, ask your RCP (Réunion de concertation pluridisciplinaire — multidisciplinary tumor board) whether your case has been reviewed and whether all molecular tests mandated by INCa guidelines have been performed.

Netherlands

The IKNL (Integraal Kankercentrum Nederland — Netherlands Comprehensive Cancer Organisation) publishes national CRC guidelines that closely follow ESMO. EMA-approved drugs are generally reimbursed through the national Zorgverzekeringswet (health insurance) system, with some newer agents subject to temporary access arrangements (Article 2b). DPYD testing is required per EMA labeling.

• Antoni van Leeuwenhoek / Netherlands Cancer Institute (NKI-AVL) (Amsterdam) — the Netherlands’ premier cancer center; strong CRC molecular profiling and clinical trials program — +31-20-512-9111
• Radboud University Medical Center (Nijmegen) — major academic center with comprehensive GI oncology and active CRC research
• Erasmus MC Cancer Institute (Rotterdam) — strong GI surgical and oncology program

Spain

SEOM (Sociedad Española de Oncología Médica) guidelines are the primary clinical reference and mirror ESMO. Reimbursement is managed through Spain’s national health system (SNS) and AEMPS. Access to newer agents can vary between autonomous communities.

• Vall d’Hebron Institute of Oncology (VHIO) (Barcelona) — one of Europe’s leading oncology research centers; comprehensive early-phase and CRC-specific trials — +34-93-489-4394
• MD Anderson Cancer Center Madrid (Madrid) — part of the MD Anderson network; GI oncology focus; English-speaking staff — +34-91-277-5727
• Hospital Clínico San Carlos (Madrid) and Hospital Universitario 12 de Octubre (Madrid) — major public centers with CRC expertise

Italy

AIOM (Associazione Italiana di Oncologia Medica) guidelines govern clinical practice. AIFA (Agenzia Italiana del Farmaco) manages reimbursement; some newer targeted agents are reimbursed conditionally through the Law 648 mechanism (compassionate use) while full reimbursement is evaluated. DPYD testing is required per EMA labeling.

• Istituto Europeo di Oncologia (IEO) (Milan) — leading private-equivalent comprehensive cancer center; strong GI oncology program — +39-02-574-89-1
• Fondazione IRCCS Istituto Nazionale Tumori (INT) (Milan) — Italy’s national tumor institute; extensive CRC clinical trials; public center — +39-02-239-02-1
• Istituto Nazionale Tumori “Fondazione Pascale” (Naples) — major southern Italian cancer center; active in CRC and immunotherapy research — +39-081-590-31-11
• Istituto Oncologico Veneto (IOV-IRCCS) (Padova) — northern Italy comprehensive cancer center with CRC molecular tumor board

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) generally approves CRC therapies 12–24 months after FDA approval for targeted agents, though Japan has contributed significantly to global CRC trials (the PARADIGM trial was Japanese-led and established RAS wild-type left-sided tumor biology for anti-EGFR use).

Japan-specific features unique globally:

• PSK / Krestin (polysaccharide-K): Approved by PMDA and reimbursed by Japan’s national health insurance as adjuvant immunotherapy for colorectal cancer. Used alongside standard chemotherapy for decades. PSK is not approved or reimbursed anywhere else in the world.
• Fruquintinib (Fruzaqla): PMDA approval September 24, 2024. Japan was the second country in the world (after China’s September 2018 approval) to approve fruquintinib, and well ahead of EMA (July 2024) and ahead of FDA (November 2023) in this sequence. Reimbursed under Japan’s national health insurance.
• Tegafur-uracil (UFT): Used in Japan’s adjuvant setting for stage II/III colon cancer as an oral fluoropyrimidine alternative; not commonly used in the US or Europe.
• CAPOX preferred over FOLFOX: JSCCR 2022 guidelines generally favor CAPOX (capecitabine + oxaliplatin) over FOLFOX for adjuvant treatment, partly due to patient convenience and Japanese pharmacokinetic data.

The JSCCR (Japanese Society for Cancer of the Colon and Rectum) 2022 guidelines are the primary clinical reference and are broadly aligned with NCCN and ESMO with the above Japan-specific differences.

Named specialist centers:

• National Cancer Center Hospital (Tokyo) — Japan’s premier cancer center; comprehensive CRC program; international patient services available — +81-3-3542-2511
• National Cancer Center Hospital East (Kashiwa, Chiba) — research-focused campus; strong CRC clinical trials — +81-4-7133-1111
• Shizuoka Cancer Center (Shizuoka) — dedicated cancer hospital; CRC molecular tumor board — +81-55-989-5222
• Osaka International Cancer Institute (Osaka) — leading western Japan cancer center — +81-6-6945-1181
• Aichi Cancer Center (Nagoya) — major central Japan cancer center with CRC specialty — +81-52-762-6111

If you are being treated in Japan, ask whether PSK has been discussed as part of your adjuvant plan, and whether your tumor has been profiled for RAS/BRAF/MSI under JSCCR guidelines.

South Korea’s National Health Insurance Service (NHIS) covers most EMA/FDA-approved targeted CRC agents, often with a delay of 1–3 years after initial approval. Korea has one of the highest colon cancer incidence rates globally and invests significantly in CRC research.

K-MASTER Program: Korea’s national precision oncology initiative (Korean Molecular Tumor Board for Advanced Solid Tumors Research) enrolls patients with advanced cancers for comprehensive molecular profiling and matches them to targeted therapies or clinical trials. One of the most ambitious national precision medicine programs in Asia.

Named specialist centers:

• National Cancer Center Korea (Goyang, Gyeonggi-do) — Korea’s dedicated national cancer hospital; leading CRC surgical and oncology program — +82-31-920-1234
• Asan Medical Center (Seoul) — largest hospital in Korea; comprehensive GI oncology; internationally recognized CRC program — +82-2-3010-3114
• Samsung Medical Center (Seoul) — leading tertiary center; strong CRC molecular tumor board and clinical trials — +82-2-3410-2114
• Seoul National University Hospital (SNUH) (Seoul) — premier academic medical center; CRC research and surgery — +82-2-2072-2114
• Yonsei Cancer Center, Severance Hospital (Seoul) — comprehensive cancer center; strong GI oncology and immunotherapy program — +82-2-2228-8000

If you are being treated in Korea, ask whether your case has been enrolled in K-MASTER molecular profiling, and whether your NHIS insurance covers the targeted agent your oncologist recommends.

China’s National Medical Products Administration (NMPA) regulates drug approvals. The CSCO (Chinese Society of Clinical Oncology) CRC guidelines are updated annually and are broadly aligned with NCCN and ESMO, with some China-specific agents and preferences.

China-specific landmark: Fruquintinib (Elunate) was first approved in the world by the NMPA in September 2018 — five years before the US FDA approval (November 2023) and six years before EMA approval (July 2024). Fruquintinib was developed by HUTCHMED (formerly Hutchison China MediTech), a Hong Kong-listed biopharmaceutical company, and was initially approved specifically on the basis of the FRESCO trial conducted in Chinese patients. This makes China’s experience with fruquintinib the longest globally.

China’s National Reimbursement Drug List (NRDL) is updated annually; targeted agents approved by NMPA are increasingly included, though access varies by province and hospital tier.

Named specialist centers:

• Fudan University Shanghai Cancer Center (FUSCC) (Shanghai) — China’s leading cancer center; comprehensive CRC program; extensive international collaborations — +86-21-6417-5590
• Sun Yat-sen University Cancer Center (SYSUCC) (Guangzhou) — premier cancer center in southern China; strong CRC research program — +86-20-8734-3438
• Beijing Cancer Hospital (Beijing) — major GI oncology center; affiliated with Peking University — +86-10-8819-6688
• Peking Union Medical College Hospital (PUMCH) (Beijing) — China’s top academic medical center; comprehensive oncology program — +86-10-6915-6114

If you are being treated in China, ask whether your hospital is a Grade 3A (top-tier) center, whether CSCO 2023/2024 guidelines are being followed, and whether fruquintinib is appropriate for your situation given China’s extensive real-world experience with this agent.

The Therapeutic Goods Administration (TGA) approves drugs for the Australian market. The Pharmaceutical Benefits Scheme (PBS), managed by the federal government, determines whether drugs are subsidized for Australian patients. Without PBS listing, patients pay full price, which for targeted oncology agents can be tens of thousands of dollars per month.

Australia’s global leadership in ctDNA research: Australia is a world leader in ctDNA (circulating tumor DNA)-guided therapy research. The DYNAMIC trial — which tested whether ctDNA could guide decisions about adjuvant chemotherapy in stage II colon cancer — was primarily conducted in Australia and is the landmark evidence in this emerging field. Australian oncologists have the most experience with ctDNA-guided treatment decisions globally, and this approach is more commonly used in Australia than anywhere else, though it remains investigational worldwide.

PBS listing highlights: Bevacizumab (2010), cetuximab (2009), trifluridine/tipiracil (2017), regorafenib (2014), pembrolizumab for dMMR mCRC (2020), encorafenib + cetuximab for BRAF V600E mCRC PBS-listed. Fruquintinib, tucatinib + trastuzumab, and nivolumab + ipilimumab first-line under PBS review as of mid-2026.

eviQ: The eviQ platform (Cancer Institute NSW, eviQ.org.au) is the primary online protocol reference for Australian oncologists — equivalent to NCCN guidelines in the US. COSA (Clinical Oncology Society of Australia) guidelines complement eviQ for broader oncology practice.

Named specialist centers:

• Peter MacCallum Cancer Centre (Melbourne, Victoria) — Australia’s leading cancer center; comprehensive CRC program; strong molecular tumor board; active in ctDNA and immunotherapy trials — +61-3-8559-5000
• Royal Prince Alfred Hospital — Chris O’Brien Lifehouse (Sydney, NSW) — major NSW cancer center; GI oncology expertise; multidisciplinary CRC program — +61-2-9515-6111
• Olivia Newton-John Cancer Wellness & Research Centre / Austin Health (Melbourne, Victoria) — comprehensive cancer center; CRC clinical trials; immunotherapy expertise — +61-3-9496-3000
• Princess Alexandra Hospital — Cancer Care Services (Brisbane, Queensland) — Queensland’s major cancer center; CRC surgery and oncology — +61-7-3176-2111
• Sir Charles Gairdner Hospital — Linear Cancer Centre (Perth, Western Australia) — primary cancer center for WA; GI oncology program

If you are being treated in Australia, ask whether ctDNA monitoring is available at your center as part of a clinical trial, and confirm your agent is PBS-listed so you are not exposed to unexpected out-of-pocket costs.

Health Canada approves drugs for the Canadian market. Funding decisions are largely provincial, not federal. The pan-Canadian Oncology Drug Review (pCODR), now operating under CADTH (Canadian Agency for Drugs and Technologies in Health), issues funding recommendations that individual provinces then adopt on their own timelines. This creates significant provincial variation: a drug approved federally and recommended by pCODR may be funded in Ontario months or years before it is funded in more remote provinces.

Fruquintinib (Fruzaqla): Health Canada NOC September 10, 2024; CDA-AMC (pCODR) review in progress; price reduction needed for cost-effectiveness (~87% reduction required at $50K/QALY threshold). Provincial funding pending pCODR recommendation.

Provincial formulary timing variation:

• Ontario (OHDB — Ontario Health Drug Benefit): Typically among the fastest provinces to adopt pCODR recommendations
• Quebec (INESSS): Independent assessment process; often 6–18 months behind Ontario for targeted agents
• British Columbia (BC PharmaCare): Generally follows pCODR; BC Cancer provincial protocols are a major clinical reference
• Remote provinces (New Brunswick, Nova Scotia, PEI, Newfoundland): Often 12–24 months behind Ontario; patients may need to advocate for exceptional access

If a recommended drug is not yet funded in your province, ask your oncologist about the Exceptional Access Program (Ontario) or equivalent provincial mechanism, or manufacturer compassionate-use programs.

Named specialist centers:

• Princess Margaret Cancer Centre (Toronto, ON) — one of the world’s top 5 cancer centers; comprehensive CRC program; extensive clinical trials — +1-416-946-4501
• BC Cancer — Vancouver Centre (Vancouver, BC) — primary BC cancer center; strong CRC program; BC Cancer provincial protocols — +1-604-877-6000
• McGill University Health Centre — Cedars Cancer Centre (Montreal, QC) — Quebec’s leading academic cancer center; French and English services — +1-514-934-1934
• Sunnybrook Health Sciences Centre — Odette Cancer Centre (Toronto, ON) — major Toronto cancer center; GI oncology specialty; radiation and systemic therapy — +1-416-480-6100
• The Ottawa Hospital Cancer Centre (Ottawa, ON) — bilingual; major eastern Ontario CRC program — +1-613-737-7700
• Tom Baker Cancer Centre (Calgary, AB) — primary Alberta cancer center; CRC clinical trials; molecular tumor board — +1-403-521-3166
• Cross Cancer Institute (Edmonton, AB) — second major Alberta cancer center; comprehensive GI oncology — +1-780-432-8771
• QEII Health Sciences Centre — Cancer Care Nova Scotia (Halifax, NS) — primary maritime provinces cancer center — +1-902-473-6000

India

Drug approvals in India are managed by CDSCO (Central Drugs Standard Control Organisation). India has a significant advantage in cancer care cost: biosimilars of bevacizumab, cetuximab, and trastuzumab are broadly available at a fraction of US or European prices, making these agents accessible to more patients. Pembrolizumab is approved for dMMR CRC. NCCN guidelines are widely referenced in Indian oncology practice, alongside ICMR (Indian Council of Medical Research) guidelines.

• Tata Memorial Centre (Mumbai, Maharashtra) — India’s premier government cancer hospital; comprehensive CRC program; high-volume surgical center — +91-22-2417-7000
• Rajiv Gandhi Cancer Institute and Research Centre (New Delhi) — leading private cancer hospital in north India; comprehensive GI oncology — +91-11-4700-5000
• All India Institute of Medical Sciences (AIIMS) (New Delhi) — India’s top academic medical institution; oncology department with broad CRC expertise — +91-11-2658-8500
• Adyar Cancer Institute (Cancer Institute WIA) (Chennai, Tamil Nadu) — one of Asia’s oldest cancer centers; strong GI oncology program; affordable care — +91-44-2235-0241
• HCG Cancer Centre (Bangalore / multiple locations) — largest private oncology network in India; comprehensive CRC program across 25+ centers

Singapore

The Health Sciences Authority (HSA) regulates drug approvals in Singapore. Singapore functions as a major medical hub for Southeast Asia, with most EMA and FDA-approved CRC agents available, though pricing without subsidization is high. MediShield Life and MediFund provide partial coverage for subsidized patients at public hospitals.

• National Cancer Centre Singapore (NCCS) (Singapore) — Singapore’s dedicated cancer center; comprehensive CRC program; molecular tumor board; active in CRC clinical trials — +65-6436-8000
• Singapore General Hospital Cancer Centre (Singapore) — public sector comprehensive cancer care; large-volume GI oncology program
• National University Cancer Institute Singapore (NCIS) (Singapore) — academic cancer center; CRC clinical trials and molecular profiling

Latin America presents a wide spectrum of access to advanced CRC therapies. Immunotherapy access is significantly limited by cost across most of the region. Biosimilars of bevacizumab and cetuximab are improving access to these biologics. Targeted agents approved in the US and Europe are often available in major private hospitals, but may be years away from public system reimbursement.

Brazil

Drug approvals are managed by ANVISA (Agência Nacional de Vigilância Sanitária). Brazil has a two-track system: SUS (Sistema Único de Saúde) provides free care but access to newer targeted agents is limited; private sector hospitals offer broader access.

• AC Camargo Cancer Center (São Paulo) — Brazil’s leading comprehensive cancer center; international partnerships; strong CRC clinical trials program — +55-11-2189-5000
• Hospital Sírio-Libanês (São Paulo) — Brazil’s most prestigious private hospital; comprehensive GI oncology; molecular tumor board — +55-11-3155-0200
• INCA (Instituto Nacional de Câncer) (Rio de Janeiro) — Brazil’s national cancer institute; largest public CRC program in Brazil

Mexico

COFEPRIS manages drug approvals. Mexico has both a public system (IMSS, ISSSTE) and a private sector. Access to targeted agents in the public system is very limited; private sector access is broader but costly.

• Instituto Nacional de Cancerología (INCan) (Mexico City) — Mexico’s national cancer reference center; largest public CRC program; clinical trials — +52-55-5628-0400
• Hospital Ángeles Pedregal / Centro Oncológico (Mexico City) — leading private oncology center; broader access to targeted agents

Argentina

ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) approves drugs. Argentina has a mixed public-private system. Obra social (union health funds) and prepaga (private insurance) coverage for targeted agents varies significantly.

• Instituto Alexander Fleming (Buenos Aires) — Argentina’s leading private oncology center; comprehensive CRC program; active in international trials
• Hospital Italiano de Buenos Aires (Buenos Aires) — major academic medical center; comprehensive oncology program; multidisciplinary CRC boards

Colombia

INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) manages approvals. Colombia’s mandatory health insurance system (EPS) covers some targeted agents but access can be inconsistent. Major cities have sophisticated cancer care.

• Fundación Valle del Lili (Cali) — Colombia’s leading comprehensive cancer center; strong CRC research program; international collaborations
• Instituto Nacional de Cancerología de Colombia (Bogotá) — national cancer reference center; public sector CRC care

Saudi Arabia

The Saudi Food and Drug Authority (SFDA) approves drugs in Saudi Arabia. Vision 2030 health investments have significantly expanded cancer care infrastructure. CCHI (Council of Cooperative Health Insurance) covers most approved oncology agents for insured patients.

• King Faisal Specialist Hospital and Research Centre (KFSHRC) (Riyadh) — the largest and most advanced cancer center in the Gulf region; comprehensive CRC program; molecular tumor board; treats patients from across the Arab world — +966-11-442-7272
• National Guard Health Affairs — King Abdulaziz Medical City (Riyadh) — major tertiary center; comprehensive oncology services

Jordan

• King Hussein Cancer Center (KHCC) (Amman) — the premier cancer center for the Arab world and East Africa; treats patients from more than 30 countries; Joint Commission International (JCI)-accredited; dedicated international patient services department; comprehensive CRC program with molecular profiling — +962-6-539-9021

KHCC is widely considered the most important referral destination for patients from the Middle East and East Africa who cannot access care in the US or Europe. International patients are welcomed and supported.

United Arab Emirates

The Ministry of Health and Prevention (MoHAP) and Dubai Health Authority (DHA) manage drug approvals and oversight in the UAE. The UAE hosts several internationally affiliated hospital networks.

• Cleveland Clinic Abu Dhabi (Abu Dhabi) — operated by Cleveland Clinic (US); comprehensive oncology; English-speaking; international patient services — +971-2-501-9000
• American Hospital Dubai (Dubai) — JCI-accredited; comprehensive cancer center; English-speaking; American Board-certified oncologists — +971-4-336-7777

Egypt

• National Cancer Institute Cairo University (NCI Cairo) (Cairo) — Egypt’s primary cancer reference center; largest oncology program in North Africa; high-volume CRC program — +20-2-2364-8000

South Africa

SAHPRA (South African Health Products Regulatory Authority) approves drugs. South Africa has the most developed cancer care infrastructure in sub-Saharan Africa, with a significant gap between private and public sector access.

• Groote Schuur Hospital Cancer Centre (Cape Town) — South Africa’s leading academic cancer center; CRC program through UCT Faculty of Health Sciences — +27-21-404-9111
• Netcare Milpark Hospital Oncology Centre (Johannesburg) — leading private oncology center; comprehensive CRC care; broader access to targeted agents

• Which guidelines does your center follow? (NCCN, ESMO, JSCCR, CSCO, national guidelines) — Understanding which guideline your oncologist is following helps you compare to what you read in US-based patient resources.
• Has my tumor been tested for everything recommended? Ask specifically about MSI/MMR, KRAS/NRAS, BRAF V600E, HER2 amplification, and DPYD genotyping. Not all countries require or routinely perform all tests.
• Is the drug you are recommending approved and reimbursed in this country? Approval and reimbursement are different — a drug can be approved but not covered, leaving you with a large out-of-pocket bill.
• Is there a Cancer Drugs Fund, exceptional access, or compassionate-use mechanism I can apply for if the drug I need isn’t reimbursed yet?
• Are there clinical trials here that would give me access to drugs not yet approved locally? Clinical trial availability varies significantly by country and center.
• How does my center’s experience with this cancer compare to a national reference center? For rare presentations (BRAF V600E, KRAS G12C, HER2-positive, dMMR), national specialty centers typically have far more experience than general oncology practices.
• Can I get a second opinion at a named comprehensive cancer center in this country before starting treatment?
• If I travel to the US or another country for treatment, can my records and tissue samples be transferred? Ensure tumor tissue is preserved and molecular testing results are portable.

• Bevacizumab as adjuvant therapy (stages II–III) FAILED
  Multiple large trials (NSABP C-08, AVANT, QUASAR 2) tested adding bevacizumab (Avastin) to standard adjuvant chemotherapy after surgery. None showed benefit in disease-free survival, and bevacizumab added toxicity. It remains useful in metastatic CRC but does not help after curative surgery.
• Cetuximab as adjuvant therapy (stage III) FAILED
  The N0147 trial tested adding cetuximab to FOLFOX adjuvant chemotherapy in KRAS wild-type stage III colon cancer. It did not improve outcomes and increased toxicity. Anti-EGFR agents are not used in the adjuvant setting.
• Irinotecan in adjuvant therapy FAILED
  Several trials (CALGB 89803, PETACC-3, ACCORD 02) tested adding irinotecan to 5-FU/leucovorin as adjuvant therapy for stage III colon cancer. None demonstrated improved disease-free or overall survival compared to standard regimens. Irinotecan is used in metastatic disease (as FOLFIRI) but not in the adjuvant setting.
• Goshajinkigan (TJ-68) for oxaliplatin neuropathy prevention FAILED
  The GENIUS trial found that this traditional Japanese herbal medicine (Kampo) significantly worsened oxaliplatin-induced peripheral neuropathy (HR 1.908, p=0.007) rather than preventing it. Do not use goshajinkigan to prevent or treat chemotherapy neuropathy.
• Edrecolomab (Panorex) WITHDRAWN
  This early monoclonal antibody targeting EpCAM showed initial promise in a German trial in the 1990s and was briefly approved in Germany. Subsequent larger trials failed to confirm benefit, and it was withdrawn from the market.
• Routine hepatic artery infusion (HAI) chemotherapy for all liver metastases DE-ADOPTED
  While HAI remains a niche option at highly specialized centers (notably Memorial Sloan Kettering) for select patients with liver-only metastases, its routine use as a standard approach was de-adopted as systemic therapies improved. It is not recommended as a standard first-line approach for liver metastases.
• Levamisole (beyond historical use) DE-ADOPTED
  Levamisole plus 5-FU was a standard adjuvant regimen in the 1990s following the landmark INT-0035 trial. It was superseded when leucovorin-based regimens and then oxaliplatin combinations (FOLFOX, CAPOX) proved superior. Levamisole is no longer used in colon cancer treatment.

• Adenocarcinoma — the most common type of colon cancer, beginning in the gland cells lining the colon.
• Adenoma — a type of polyp that is a true precancer and can transform into cancer over years.
• Adjuvant chemotherapy — chemotherapy given after surgery to destroy residual microscopic cancer and reduce recurrence risk.
• Anastomosis — the surgical reconnection of two bowel ends after a segment is removed.
• Anti-EGFR therapy — drugs (cetuximab, panitumumab) blocking the EGFR protein; effective only in RAS wild-type tumors, most beneficial in left-sided disease.
• Anti-VEGF therapy — bevacizumab; interferes with tumor blood supply; combined with chemotherapy in metastatic disease.
• BRAF V600E — a mutation in roughly 8–12% of colon cancers; now treatable with targeted drug combinations.
• CAPOX / CAPEOX — adjuvant regimen of capecitabine pills plus intravenous oxaliplatin.
• CEA — carcinoembryonic antigen; a protein measured by blood test to track trends during and after treatment.
• Colectomy — surgical removal of part or all of the colon.
• Complete mesocolic excision — surgical technique removing the tumor with the intact mesentery containing lymph nodes and vessels.
• ctDNA — circulating tumor DNA; fragments of tumor DNA detectable in blood, used to assess residual disease and monitor for recurrence.
• dMMR — mismatch-repair-deficient; a tumor whose DNA proofreading system is broken. Equivalent to MSI-high. Predicts benefit from immunotherapy.
• DPYD — gene controlling fluoropyrimidine metabolism; certain variants raise severe toxicity risk; testing advised before chemotherapy.

• Fluoropyrimidine — the backbone drug class of colon cancer chemotherapy (5-fluorouracil IV or capecitabine oral).
• FOLFOX — regimen of 5-fluorouracil, leucovorin, and oxaliplatin; used in adjuvant and metastatic settings.
• FOLFIRI — regimen of 5-fluorouracil, leucovorin, and irinotecan; used mainly in metastatic disease.
• FOLFOXIRI — intensive regimen combining all four drugs; used in fitter patients with metastatic disease.
• Grade — how abnormal cancer cells appear; low-grade looks more normal, high-grade more disorganized.
• HER2 amplification — extra copies of HER2 gene in a small share of colon cancers; targetable with HER2-directed therapy.
• HIPEC / CRS — cytoreductive surgery plus heated intraperitoneal chemotherapy; used for selected peritoneal disease.
• Immunotherapy — checkpoint inhibitor drugs that activate the immune system against cancer; highly effective in dMMR/MSI-high colon cancer.
• Leucovorin — vitamin-related drug given with 5-fluorouracil to enhance its effect.
• Lynch syndrome — inherited mismatch repair gene mutation raising risk of colon and other cancers; first-degree relatives have 50% chance of carrying it.
• Metastasis — cancer spread to a distant organ, most often liver or lungs; defines stage IV.
• MSI-high — microsatellite instability-high; equivalent to dMMR; predicts benefit from immunotherapy.
• Neoadjuvant therapy — treatment given before surgery.
• Neuropathy — nerve damage causing numbness, tingling, or pain in hands and feet; the main long-term side effect of oxaliplatin.
• NGS — next-generation sequencing; comprehensive genetic testing of the tumor to guide treatment.

• Ostomy — surgically created opening on the abdomen for stool passage into a pouch; often temporary in colon cancer.
• Oxaliplatin — chemotherapy drug added to the fluoropyrimidine backbone; effective but cumulative neuropathy limits duration.
• Palliative care — specialized care for symptom relief and quality of life; runs alongside active treatment; not hospice.
• Pathologic stage — definitive stage determined after surgery based on examination of removed tissue.
• Polyp — a growth on the colon wall; adenomas and sessile serrated lesions can become cancer.
• RAS (KRAS / NRAS) — genes mutated in roughly half of colon cancers; RAS mutation means anti-EGFR drugs will not work.
• Resectable — able to be completely removed by surgery; determines whether the goal in stage IV can be cure.
• Sidedness — right-sided versus left-sided tumor location; influences biology and treatment response.
• Stage — measure of how far cancer has spread (0 through IV); the strongest predictor of outcome.
• Surveillance — structured schedule of blood tests, scans, and colonoscopy after curative treatment to detect recurrence early.
• TNM system — staging system combining tumor depth (T), lymph node involvement (N), and distant spread (M).
• Tumor board — meeting where specialists from multiple fields discuss an individual patient’s case together.
• Wild-type — a gene in its normal, unmutated form.

Guidelines:

• NCCN Clinical Practice Guidelines — Colon Cancer (current version)
• ESMO Clinical Practice Guidelines for early and metastatic colorectal cancer
• AGA / USMSTF Guidelines on post-polypectomy and post-cancer surveillance

Landmark trials referenced in this guide:

• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials
• NCCN Guidelines for Patients (nccn.org/patientresources) — Free patient-friendly colon cancer guidelines
• National Cancer Institute (cancer.gov/types/colorectal) — Comprehensive information and trial search (1-800-4-CANCER)
• Colorectal Cancer Alliance — ccalliance.org, 877-422-2030
• Fight Colorectal Cancer — fightcrc.org
• American Cancer Society — cancer.org, 800-227-2345